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A B S T R A C T
Background
Although superficial thrombophlebitis of the upper extremity represents a frequent complication of intravenous catheters inserted into
the peripheral veins of the forearm or hand, no consensus exists on the optimal management of this condition in clinical practice.
Objectives
To summarise the evidence from randomised clinical trials (RCTs) concerning the efficacy and safety of (topical, oral or parenteral)
medical therapy of superficial thrombophlebitis of the upper extremity.
Search methods
The Cochrane Vascular Group Trials Search Co-ordinator searched the Specialised Register (last searched April 2015) and the Cochrane
Register of Studies (2015, Issue 3). Clinical trials registries were searched up to April 2015.
Selection criteria
RCTs comparing any (topical, oral or parenteral) medical treatment to no intervention or placebo, or comparing two different medical
interventions (e.g. a different variant scheme or regimen of the same intervention or a different pharmacological type of treatment).
Data collection and analysis
We extracted data on methodological quality, patient characteristics, interventions and outcomes, including improvement of signs and
symptoms as the primary effectiveness outcome, and number of participants experiencing side effects of the study treatments as the
primary safety outcome.
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Main results
We identified 13 studies (917 participants). The evaluated treatment modalities consisted of a topical treatment (11 studies), an oral
treatment (2 studies) and a parenteral treatment (2 studies). Seven studies used a placebo or no intervention control group, whereas
all others also or solely compared active treatment groups. No study evaluated the effects of ice or the application of cold or hot
bandages. Overall, the risk of bias in individual trials was moderate to high, although poor reporting hampered a full appreciation of
the risk in most studies. The overall quality of the evidence for each of the outcomes varied from low to moderate mainly due to risk of
bias and imprecision, with only single trials contributing to most comparisons. Data on primary outcomes improvement of signs and
symptoms and side effects attributed to the study treatment could not be statistically pooled because of the between-study differences
in comparisons, outcomes and type of instruments to measure outcomes.
An array of topical treatments, such as heparinoid or diclofenac gels, improved pain compared to placebo or no intervention. Compared
to placebo, oral non-steroidal anti-inflammatory drugs reduced signs and symptoms intensity. Safety issues were reported sparsely
and were not available for some interventions, such as notoginseny creams, parenteral low-molecular-weight heparin or defibrotide.
Although several trials reported on adverse events with topical heparinoid creams, Essaven gel or phlebolan versus control, the trials
were underpowered to adequately measure any differences between treatment modalities. Where reported, adverse events with topical
treatments consisted mainly of local allergic reactions. Only one study of 15 participants assessed thrombus extension and symptomatic
venous thromboembolism with either oral non-steroidal anti-inflammatory drugs or low-molecular-weight heparin, and it reported no
cases of either. No study reported on the development of suppurative phlebitis, catheter-related bloodstream infections or quality of
life.
Authors’ conclusions
The evidence about the treatment of acute infusion superficial thrombophlebitis is limited and of low quality. Data appear too
preliminary to assess the effectiveness and safety of topical treatments, systemic anticoagulation or oral non-steroidal anti-inflammatory
drugs.
P L A I N L A N G U A G E S U M M A R Y
Treatment for superficial infusion thrombophlebitis of the upper extremity
Background
Superficial thrombophlebitis is an inflammatory condition of the veins just below the surface of the skin. The development of superficial
thrombophlebitis frequently complicates the insertion of needles into the veins for catheters to give medication or fluids in hospitalised
patients. The best treatment for these blood clots in the hands and arms remains unclear. While local treatment has the potential to
improve the painful symptoms and patient discomfort, it may not prevent complications, including infection or the extension or transit
of the clot into the deep vein system.
Study characteristics and key results
In the current review, which looked for studies up to April 2015, we identified 13 studies involving 917 participants. Eleven studies
evaluated topical treatments (medication applied to the skin), two trials studied an oral treatment, and two studies assessed a parenteral
treatment (via injection or infusion). Seven studies used a control group that received no treatment or a placebo, whereas all others
also or solely compared two active treatment groups. No study evaluated the effects of ice or the application of cold or hot bandages.
Overall, topical treatments resulted in a higher and faster improvement of the clinical signs and symptoms compared to placebo or no
intervention. Reporting on safety data was limited, with no available information on some treatments (notoginseny creams, parenteral
low-molecular-weight heparin or defibrotide). Although some studies reported on harmful side effects with topical heparinoid creams,
Essaven gel or phlebolan, the trials were too small in size to adequately measure any differences between treatments. Reported side
effects of topical treatments consisted mainly of local allergic reactions. Only one study with 15 participants assessed anything other
than localised control of the condition. That study reported on extension of the clot or symptomatic venous thromboembolism (when
the blood clot breaks loose and travels in the blood stream), observing no cases when treated orally with non-steroidal anti-inflammatory
drugs or with low-molecular-weight heparin. None of the studies reported on the development of suppurative or septic phlebitis (when
pus is formed inside the vein or around the vein wall or both), catheter-related bloodstream infections or quality of life.
Quality of the evidence
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Some of the included studies may have been biased due to design limitations, but we could not always assess this risk because the original
researchers did not always provide enough information to judge. The overall quality of the evidence for each of the outcomes varied
from low to moderate, mainly because the studies had design flaws or were very small. We could not analyse data on primary outcomes
together because the trials examined different treatments, in different ways, looking at different outcomes. In short, the evidence about
the treatment of acute infusion superficial thrombophlebitis is limited and of low quality, and we do not have enough information to
recommend the use of any of the treatments studied.
B A C K G R O U N D
Description of the condition
Superficial thrombophlebitis of the upper extremity is a relatively
frequent complication of intravenous catheters inserted into the
peripheral veins of the upper extremity, usually in the forearm or
hand, to administer fluids, nutrients, drugs and blood products
in hospitalised patients (De la Sierra 1989; Maki 1991; Tagalakis
2002; Tager 1983). While there is no standard diagnostic crite-
rion or group of diagnostic criteria, distinctive clinical findings for
superficial thrombophlebitis of the upper extremity include pain,
tenderness, warmth, erythema, swelling and a palpable cord on the
cannulated vein. Depending on the definition used and the type of
patients evaluated, the incidence of superficial thrombophlebitis
of the upper extremity has varied broadly between 0.1% to 70%
(Bregenzer 1998; Collin 1975; Maki 1991; Monreal 1999; Soifer
1998; Tagalakis 2002; Tager 1983). The condition usually appears
12 to 36 hours after cannulation, and peaks at 72 to 96 h although
some patients have been diagnosed with thrombophlebitis more
than 15 days after catheter placement, which may depend on the
definition and diagnostic methods used (Collin 1975; Gaukroger
1988; Hershey 1984; Maki 1987; Tager 1983; Tomford 1984).
The duration of superficial thrombophlebitis of the upper extrem-
ity lasts around 24 to 96 hours or longer depending on the severity,
concomitant diseases and the provision of symptomatic treatment
(Hershey 1984).
Superficial thrombophlebitis of the upper extremity is believed to
result from the activation of the inflammatory and coagulation
cascades by a variety of triggering factors that irritate and dam-
age the vein wall, including mechanical factors such as traumatic
injury of the vessel wall by the catheter, infective factors like the
bacterial colonisation of the intravascular segment of the catheter,
or damage to the vessel wall by chemicals. Preliminary data suggest
that, as for deep vein thrombosis of the extremities, the formation
of a thrombus within the vein accompanies and often precedes
the development of the clinical signs and symptoms that charac-
terise superficial thrombophlebitis (Everitt 1997). Different stud-
ies have described risk factors for superficial thrombophlebitis of
the upper extremity, although results have not always been con-
sistent (Maki 1991; Tagalakis 2002). Duration of the catheterisa-
tion, catheter material and size, type of infusion (e.g. hypertonic
solutions, intravenous antibiotics, chemotherapeutic agents), and
catheter-related infections were all associated with the risk and du-
ration of superficial thrombophlebitis (Collin 1975; Fonkalsrud
1971; Gaukroger 1988; Hershey 1984; Maki 1987; Maki 1991;
Monreal 1999; Tagalakis 2002; Tager 1983; Timmer 1991). Pa-
tient-related risk factors such as the ’quality’ of the cannulated
veins or underlying medical diseases (e.g. active cancer, immunod-
eficiencies, infections or skin diseases) also seem to influence the
development of superficial thrombophlebitis (Gaukroger 1988;
Hershey 1984; Tager 1983; Tomford 1984).
While superficial thrombophlebitis of the upper extremity is
generally considered a trivial nosocomial complication, it can
nonetheless cause substantial patient discomfort and require the
removal of the catheter with insertion of a new cannulae at a dif-
ferent site. Repeated episodes of superficial thrombophlebitis can
lead to venous access difficulties and placement of a central venous
catheter with resulting delayed administration of parenteral med-
ications and lengthened hospital stay. Occasionally, serious com-
plications can occur; one of the most threatening local complica-
tions is a supervening infection with the development of suppu-
rative superficial thrombophlebitis, which occurs in up to 2% of
peripheral vein catheter insertions (Lee 2009; Stein 1970; Stratton
1982; Tomford 1984). Patients with superficial thrombophlebitis
of the upper extremity also have an increased risk of catheter-re-
lated bloodstream infections, which occur in 0.1% of the cases
(Maki 1973; Maki 2006).
Description of the intervention
Superficial thrombophlebitis of the upper extremity can be pre-
vented by intermittent heparin flushes or heparin continuous in-
fusions, which Randolph 1998 reported as reducing the risk of
superficial thrombophlebitis by 39% and 45%, respectively. Reg-
ular replacement of the catheter every 48 to 72 hours has been
shown to be of no benefit compared with leaving the catheter in
place for longer periods and changing it only if clinically indicated
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(Smith 1990; Webster 2013). Once superficial thrombophlebitis
has developed, the prompt removal of the catheter is generally as-
sociated with an improvement of the clinical signs and symptoms.
In those with continued discomfort, treatment may be indicated
to reduce pain and inflammation as well as to obtain the patency
of the obstructed vein. There is no consensus on the optimal man-
agement of superficial thrombophlebitis of the upper extremity in
clinical practice, although several therapies have been proposed in
the literature, including topical and systemic medical treatments.
The 2008 guidelines of the American College of Chest Physicians
suggested treating patients experiencing symptomatic infusion su-
perficial thrombophlebitis with an oral anti-inflammatory drug,
topical diclofenac gel, or heparin gel until resolution of symptoms
or for up to two weeks (Kearon 2008). These guidelines recom-
mended against the use of systemic anticoagulation.
Why it is important to do this review
Conservative management, such as the topical application of anti-
inflammatory drugs, mainly focuses on relieving the painful symp-
toms of superficial thrombophlebitis, and it might be regarded as
sufficient to improve the acute inflammatory state and patient dis-
comfort.However, it is unclearwhether such treatment is sufficient
to prevent complications such as suppurative superficial throm-
bophlebitis or catheter-related bloodstream infections. Moreover,
the effects of treatment on the underlying thrombosis and its po-
tential extension into the deep vein system need to be evaluated.
Lastly, a benefit-harm evaluation is indicated to evaluate if routine
treatment of superficial thrombophlebitis is indicated.
O B J E C T I V E S
To summarise the evidence from randomised clinical trials (RCTs)
concerning the efficacy and safety of (topical, oral or parenteral)
medical therapy of superficial thrombophlebitis of the upper ex-
tremity.
M E T H O D S
Criteria for considering studies for this review
Types of studies
RCTs or quasi-randomised RCTs.
Types of participants
Hospitalised or ambulatory patients of any age with a diagnosis
of superficial thrombophlebitis of the upper extremity based on
presentation of symptoms and signs, including pain, tenderness,
induration or erythema in a superficial vein. Superficial throm-
bophlebitis could involve any of the following veins: cephalic vein,
median cubital vein, basilic vein, median antebrachial vein, dorsal
metacarpal veins or dorsal network veins. We did not consider
superficial thrombophlebitis of the lower extremity as this is the
subject of another Cochrane review (Di Nisio 2013).
Types of interventions
Interventions included any (topical, oral or parenteral) medical
treatment to relieve the symptoms and signs or to prevent compli-
cations of superficial thrombophlebitis (e.g. non-steroidal anti-in-
flammatory drugs or anticoagulants such as fondaparinux or low-
molecular-weight heparin).
Comparison included either an inactive control intervention (i.e.
placebo, no treatment), or another active intervention (i.e. a dif-
ferent variant scheme or regimen of the same intervention, a dif-
ferent pharmacological type of treatment).
We planned to record the use of ice or the application of cold or
hot bandages, but no trials reported this outcome.
Types of outcome measures
Primary outcomes
Effectiveness
• Reduction or resolution of symptoms (for example, pain)
• Reduction or resolution of clinical signs (for example,
induration and erythema)
We used the measures for assessing resolution as reported by the
trialists.
Safety
Number of participants experiencing one or more side effects at-
tributed to study treatment (e.g. bleeding or allergic reactions)
Secondary outcomes
Effectiveness
• Extension of superficial thrombophlebitis
• Suppurative superficial thrombophlebitis
• Catheter-related bloodstream infections
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• Symptomatic venous thromboembolism
• Quality of life (by any validated quality of life instrument)
Venous thromboembolism (VTE) comprised deep venous throm-
bosis, pulmonary embolism, or both.
Safety
Adverse events (drug-related and non drug-related, local and sys-
temic).
We planned to address all outcomes in a ’Summary of findings’
table.
Search methods for identification of studies
Electronic searches
The Cochrane Vascular Group Trials Search Co-ordinator (TSC)
searched the Specialised Register (last searched April 2015) and
theCochrane Register of Studies (CRS) http://www.metaxis.com/
CRSWeb/Index.asp (2015, Issue 3). See Appendix 1 for details of
the search strategy used to search the CRS. The Specialised Reg-
ister is maintained by the TSC and is constructed from weekly
electronic searches of MEDLINE, EMBASE, CINAHL, AMED,
and through handsearching relevant journals. The full list of the
databases, journals and conference proceedings which have been
searched, as well as the search strategies used are described in the
Specialised Register section of theCochrane Vascular Groupmod-
ule in the Cochrane Library (www.cochranelibrary.com).
The following trial databases were searched by the TSC for de-
tails of ongoing and unpublished studies using the terms ’throm-
bophlebitis’ AND ’arm’, or ’phlebitis’ AND ’arm’.
• World Health Organization International Clinical Trials
Registry http://apps.who.int/trialsearch/
• ClinicalTrials.gov http://clinicaltrials.gov/
• ISRCTN register http://www.controlled-trials.com/isrctn/
Searching other resources
We searched the reference lists of relevant papers and confer-
ence proceedings of the International Society for Thrombosis and
Hemostasis (January 2003 to December 2013) and American So-
ciety of Hematology (January 2004 to December 2013).
Data collection and analysis
Selection of studies
Two review authors (MDN, FP) independently reviewed titles
and abstracts from the database searches to determine whether
the studies seemed to meet our inclusion criteria, retrieving the
full text of all potentially relevant trials. In both title/abstract and
full text screening, these two review authors (MDN, FP) inde-
pendently made decisions regarding inclusion, resolving disagree-
ments through discussion or involvement of a third review author
(AWSR).
We were not blinded to the journal, institution or results of the
study. Where necessary, we contacted the trial investigators for ad-
ditional information to judge eligibility. We documented the rea-
sons for excluding studies in theCharacteristics of excluded studies
table. One review author (MDN) screened conference proceed-
ings and included them if adequate information could be obtained
either from the abstract or from personal communication, also
identifying potentially relevant articles from reference lists. Two
review authors (MDN, FP) independently assessed eligibility.
Data extraction and management
Two review authors (MDN, FP) independently extracted the data
from the included trials using piloted extraction forms. We re-
solved any disagreements by discussion and, if necessary, by in-
volving a third review author (AWSR).We extracted data from any
trial published in more than one report from the most complete
record, which was typically the most recent publication. However,
we checked all related trial reports for additional outcome data
or trial descriptions. Collected information includedmethodolog-
ical quality, characteristics of participants, characteristics of the
intervention and control treatment, and outcomes of interest. If
reported, we described how clinicians diagnosed the superficial
thrombophlebitis of the upper extremity.We describe themethod-
ological quality features in Assessment of risk of bias in included
studies. In addition, we extracted information on trial size, design
(parallel, factorial, cross-over; single centre, multicentre), setting
(hospital versus ambulatory), reported primary and secondary out-
comes, sample size calculations, funding and potential conflicts
of interest. We recorded participant characteristics (whether clin-
icians diagnosed the thrombus in the superficial vein by venogra-
phy or venous ultrasonography and whether other factors, such as
age, gender or the presence of cancer or diabetes came into play) as
well as treatment characteristics (type of intervention (e.g. type of
analgesic or anti-inflammatory drug, type of anticoagulant), dos-
ing, route of administration (topical, oral, parenteral)) and type of
standardised co-interventions (e.g. removal catheters).
Assessment of risk of bias in included studies
Two review authors (MDN, FP or AWSR) independently assessed
randomisation, blinding, selective outcome reporting and ade-
quacy of analyses (Higgins 2011). We resolved disagreements by
consensus and, if necessary, AWSR acted as arbitrator. We assessed
two components of randomisation: generation of allocation se-
quences and allocation concealment.
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We considered generation of allocation sequences to denote a
randomised design if it resulted in an unpredictable allocation
schedule. Adequate mechanisms included random-number tables,
computer-generated random numbers, minimisation, coin toss-
ing, shuffling cards and drawing lots. On the other hand, we con-
sidered trials using potentially predictable allocation mechanisms,
such as alternation or the allocation of participants according to
date of birth, to be quasi-randomised (Rutjes 2009). We consid-
ered allocation concealment adequate if participants and investi-
gators responsible for participant selection were unable to predict,
before allocation, which treatment was next. Methods considered
adequate included central randomisation, pharmacy-controlled
randomisation using identical pre-numbered containers, and se-
quentially numbered, sealed, opaque envelopes (Rutjes 2009).
We considered blinding of participants and therapists to be ad-
equate if studies explicitly described experimental and control
preparations as indistinguishable, if trialists used a double-dummy
technique or if there was an attempt to blinding. For blinding of
assessors, we considered the method adequate if investigators ex-
plicitly affirmed that the trial used blinding methods on assessors.
We judged analyses as adequate (i.e. absence of attrition bias) if
trials included all or at least 95% of randomised participants in the
analysis according to the intention-to-treat principle.We classified
the item ’free of selective reporting’ (reporting bias) as at ’high risk
of bias’ if a report did not present data on all outcomes reported
in either the protocol or the Methods section. If studies presented
results for outcomes that were not mentioned in the Methods
section, we also scored them as having a ’high risk of bias’.
We planned to use the Grading of Recommendations Assessment,
Development and Evaluation (GRADE) to describe the quality of
the overall body of evidence for the primary effectiveness outcomes
(Guyatt 2008; Higgins 2011).
Measures of treatment effect
Wepresented results as summary risk ratios (RRs) for dichotomous
variables and mean differences (MDs) for all continuous variables.
We determined 95% confidence intervals (CIs) for each estimate.
For statistically significant results, we aimed to calculate the num-
ber needed to treat in order to benefit one patient (NNT) or the
number needed to treat in order to harm one patient (NNH) to
express the final results of the review.
Assessment of heterogeneity
We measured heterogeneity of the treatment effect between trials
with both the variance estimate I2 and Tau2. The I2 values of 25%,
50% and 75% correspond to low, moderate and high between-
trial heterogeneity, respectively (Higgins 2011). A Tau2 of 0.04
is typically interpreted to indicate low heterogeneity, while 0.09
indicates moderate heterogeneity, and 0.16 indicates high hetero-
geneity across trials (Spiegelhalter 2004).
Assessment of reporting biases
For the main outcomes, we planned to evaluate publication bias
and other biases related to small study size using funnel plots,
plotting the RRs on the vertical axis against their standard errors
on the horizontal axis (Sterne 2001). Funnel plot symmetry would
be expected in the absence of any bias related to small study size.
We planned to use the Egger’s test for continuous outcomes and
the Harbord-Egger’s test to assess symmetry for binary outcomes
(Harbord 2006), exploring any anomalies in stratified analyses (see
Data synthesis).
Data synthesis
Our main analyses included all eligible trials. We analysed and
presented data by stratifying for the type of intervention used.
We used standard inverse-variance, random-effects meta-analysis
to pool outcome data, and the fixed-effect model if only one study
was available. We planned to explore between-trial heterogeneity
by stratifying the main outcomes for the following trial character-
istics.
• Allocation concealment (adequate versus inadequate or
unclear).
• Blinding (adequate versus inadequate or unclear).
• Analysis in accordance with the intention-to-treat principle
(’yes’ versus ’no’ or ’unclear’).
• Trial size.
In addition, we planned to investigate the effects of the following
treatment features.
• Type of treatment (e.g. antiinflammatory versus
anticoagulant).
• Route of administration (e.g. topical versus parenteral or
oral).
• Length of treatment (one week versus longer).
• Length of follow-up (48 h versus one week versus two
weeks or longer).
Regarding patient characteristics, we planned to explore whether
the setting (ambulatory or inpatient) or the presence of cancer
caused an effect. For all categorical trial, patient and treatment
characteristics, we planned to use univariate random-effects meta-
regression models to determine whether these characteristics in-
fluenced treatment effects (Thompson 1999). We performed data
analyses in Cochrane Review Manager software, RevMan 2014.
For stratified analyses and funnel plot exploration, we planned to
use Stata 2012.
We planned to use GRADEpro 2008 software to create a ’Sum-
mary of findings’ table as suggested in the Cochrane Handbook for
Systematic Reviews of Interventions (Schünemann 2011).
Subgroup analysis and investigation of heterogeneity
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We planned no additional analyses other than those described in
Data synthesis and Sensitivity analysis.
Sensitivity analysis
If there were sufficient trials, we aimed to perform a sensitivity
analyses to control for the methodological quality of the trials. We
defined high-quality trials according to the results of the strati-
fied analyses. For example, if trials with adequate allocation con-
cealment and blinding of outcome assessors showed significantly
different results than trials without these features, we restricted
the sensitivity analysis to trials that were adequately concealed and
used blinded outcome assessors.
R E S U L T S
Description of studies
See Characteristics of included studies; Characteristics of excluded
studies; Characteristics of studies awaiting classification.
Results of the search
See Figure 1.
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Figure 1. Study flow diagram
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Following title and abstract screening, we considered 36 reports
to be potentially eligible.
We classified two studies as awaiting classification (Xiao 2004;
Xu 2001) and four studies as ongoing (CTRI/2012/05/002629;
CTRI/2013/12/004245; NCT01943006; NCT00377806).
Included studies
Following full-text analysis, we included 13 studies (Almenar
1993; Becherucci 2000; Berrazueta 1993; De Sanctis 2001;
Gouping 2003; Kowalsky 1978; Mehta 1975; Nachbur 1972;
Rathbun 2012; Rozsos 1994; Schedel 1977; Seccia 1989; Vilardel
1999) with a total of 917 participants.
The characteristics of the included studies are detailed in the sec-
tion Characteristics of included studies. Eleven studies evaluated
topical treatments (Almenar 1993; Becherucci 2000; Berrazueta
1993; De Sanctis 2001; Gouping 2003; Kowalsky 1978; Mehta
1975; Nachbur 1972; Rozsos 1994; Schedel 1977; Vilardel 1999),
two studied oral treatments (Becherucci 2000; Rathbun 2012) and
two assessed parenteral treatments (Rathbun 2012; Seccia 1989).
Six studies used a placebo control (De Sanctis 2001; Kowalsky
1978;Mehta 1975; Nachbur 1972; Schedel 1977; Vilardel 1999),
while the control group in Becherucci 2000 received no interven-
tion. All other studies also or solely compared different active treat-
ment groups (Almenar 1993; Berrazueta 1993; Gouping 2003;
Rathbun 2012; Rozsos 1994; Seccia 1989). None of the studies
randomised participants to non-pharmacological prophylaxis.
Below we provide details on the comparisons available from the
included studies. The numbering of the comparisons correspond
to the numbering in the sections Effects of interventions and Data
and analyses.
Studies evaluating a topical treatment versus inactive
control
1. Heparin gel versus placebo
Kowalsky 1978 randomised participants (n = 102) with superfi-
cial thrombophlebitis of the upper extremity caused by endove-
nous catheters after gynaecological operation to organo-hepari-
noid ointment (Hirudoid 40,000 international units (IU) per 100
g topical application) or placebo during the 10-day study period.
Mehta 1975 randomised participants (n = 100) with infusion su-
perficial thrombophlebitis caused by continuous intravenous infu-
sion of normal saline, dextrose saline, blood or other fluids to hep-
arinoid ointment (Hirudoid) or placebo cream. Study treatment
was applied daily for at least five days and continued thereafter if
symptoms persisted.
Schedel 1977 randomised participants (n = 40) with infusion su-
perficial thrombophlebitis of the upper extremity to organo-hep-
arinoid ointment (Hirudoid 40,000 topical application twice per
day) or placebo during the 6-day study period.
Vilardel 1999 randomised inpatients (n = 132) with acute infusion
superficial phlebitis secondary to indwelling intravenous catheter
to receive topical sodium bovine heparin as gel preparation (con-
taining 1000 IU/g of heparin) or placebo. Study treatment was
applied three times a day until clinical healing or for a maximum
of seven days.
2. Essaven gel versus placebo
De Sanctis 2001 randomised participants (n = 23) with infusion
superficial thrombophlebitis of the upper extremity to Essaven gel
(5 cm2 of gel corresponding to about 1 g of Essaven gel for each
application) or placebo. All participants received low-molecular-
weight heparin (enoxaparin sodium (Clexane) 0.1 mL/10 kg of
body weight once daily) during the study period of four weeks.
3. Phlebolan versus placebo
Nachbur 1972 randomised participants (n = 48) with infusion
superficial thrombophlebitis of the upper extremity caused by en-
dovenous catheters to phlebolan spray (diphenylbutazone 5%,
prednisolone 0.5%, sodium rutin sulphate 0.2%, topical applica-
tion three times per day) or placebo during the 5-day study period.
4. Topical or oral diclofenac versus no intervention
Becherucci 2000 randomised hospitalised participants (n = 120)
with infusion superficial thrombophlebitis to topical (gel 1% three
times a day) or oral diclofenac (75 mg twice a day) for 48 h versus
no intervention.
Studies evaluating a topical treatment versus active control
5 Transdermal nitroglycerine versus heparinoid gel
Almenar 1993 randomised inpatients and outpatients (n = 100)
with superficial infusion phlebitis caused by endovenous catheters
to receive six days of transdermal nitroglycerine gel 2% (2 cm2
once daily) or heparinoid gel (sulphuric polyholoside ester sodium
salt) applied three times daily. All participants had the catheter
removed.
Berrazueta 1993 randomised participants (n = 47) with infusion
thrombophlebitis of a superficial forearm vein to transdermal glyc-
eryl trinitrate ointment (2% gel solution at a daily dose of 12 mg)
or a heparinoid ointment (sulphuric polyholoside ester sodium
salt).
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6. Notoginseny cream versus heparinoid cream
Gouping 2003 included participants (n = 65) with postinfusion
superficial thrombophlebitis of the forearm and randomised them
to notoginseny cream (topical Chinese medicine containing saf-
flower, notoginseng, shiny-leaf prickly ash and rhubarb) or hep-
arinoid cream (Hirudoid cream). Both topical treatments were ap-
plied every 4 h until clinical resolution.
7. Topical versus oral Diclofenac
Becherucci 2000, described above.
8. Pentosan polysulphate sodium ointment versus
mucopolysaccharide ointment
Rozsos 1994 randomised adult participants (n = 110) with acute
infusion thrombophlebitis in one arm to pentosan polysulphate
sodiumointment 0.5%ormucopolysaccharide ointment 0.445%.
Participants received study treatments three times daily for seven
days.
Studies evaluating an oral or parenteral treatment versus
any control
Becherucci 2000 is described above.
9. Defibrotide versus no intervention
Seccia 1989 randomised outpatients and inpatients with superfi-
cial thrombophlebitis of the lower (n = 125) and upper (n = 15)
extremities to four groups. We only included the participants with
superficial thrombophlebitis of the upper extremities in this re-
view. The patients with acute superficial thrombophlebitis of the
upper extremity presented within 72 h of symptoms onset and
were randomised to either defibrotide (800 mg/d intramuscular
(IM) for four days followed by 400 mg/d IM until clinical resolu-
tion) plus standard treatment, or standard treatment alone until
clinical resolution. Standard treatment consisted of antimicrobic
therapy (bacampicillin 800 mg/d for 48 h), diclofenac 100 mg/d,
topical desoxyribonuclease and elastic compression.
10. Dalteparin versus ibuprofen
Rathbun 2012 randomised consecutive inpatients and outpatients
with superficial thrombophlebitis of the lower (n = 57) or upper
(n = 15) extremities to dalteparin (200 IU/kg subcutaneously at
presentation followed by 10,000 IU subcutaneously daily for an
additional six days) plus placebo given orally three times daily for
seven days versus ibuprofen (800 mg given orally three times daily
for seven days) plus placebo injections given daily for seven days. In
case symptoms of superficial thrombophlebitis were not resolved
at day 7 to 9, the patient received an additional seven days of the
blinded therapy provided there was no thrombus extension. This
review only included the people with superficial thrombophlebitis
of the upper extremities.
Excluded studies
We excluded 16 studies (17 reports; see Characteristics of excluded
studies). The reasons for exclusion were that participants with
upper extremity superficial thrombophlebitis were not included or
it was not possible to extract data for this group (Bergqvist 1990;
Bruni 1979;D’Amico1987;Nocker 1990;DeTullio 1989;Gorski
2005; Nocker 1991; Porters 1981; Pozza 1980; Stolle 1986), the
study was about prophylaxis of superficial thrombophlebitis of the
upper extremity (Cökmez 2003; Messing 1985; Nieto-Rodriguez
1992; Reid 1990; Wright 1985) or the study was not an RCT
(Marrapodi 1986).
Risk of bias in included studies
The risks of bias in the included studies is shown in Figure 2 and
Figure 3.
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study
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Allocation
Three studies used adequate random sequence generation (
Becherucci 2000; Rathbun 2012; Vilardel 1999), but this aspect
was unclear in the remaining studies due to poor reporting. Allo-
cation concealment was appropriate in four studies (Mehta 1975;
Nachbur 1972; Rathbun 2012; Vilardel 1999), but this was un-
clear in the remaining studies due to poor reporting.
Blinding
Blinding of participants and personnel was adequate in eight stud-
ies (Berrazueta 1993; De Sanctis 2001; Kowalsky 1978; Mehta
1975; Nachbur 1972; Rathbun 2012; Schedel 1977; Vilardel
1999), as was blinding of outcome assessment in five (Berrazueta
1993; De Sanctis 2001; Kowalsky 1978; Schedel 1977; Vilardel
1999), whereas in the other studies these biases were unclear due
to poor reporting. Seccia 1989 did not attempt blinding, so we
judged it to be at high risk of bias.
Incomplete outcome data
Five studies performed their analyses according to the inten-
tion-to-treat principle (Almenar 1993; Becherucci 2000;Gouping
2003; Kowalsky 1978; Mehta 1975) while in two additional stud-
ies we judged this domain to be at low risk of bias since the
percentage of participants not analysed was lower than 5% and
comparable between groups (Nachbur 1972; Schedel 1977). We
considered the risk of attrition bias to be high in two studies
(Berrazueta 1993; Vilardel 1999) and unclear in the remainder
(Rathbun 2012; Rozsos 1994; Seccia 1989; see also Differences
between protocol and review).
Selective reporting
We deemed 10 studies to be free of selective reporting bias
(Almenar 1993; Becherucci 2000; Berrazueta 1993; De Sanctis
2001;Mehta 1975; Nachbur 1972; Rathbun 2012; Schedel 1977;
Seccia 1989; Vilardel 1999). In Gouping 2003, the authors did
not explicitly predefine the outcomes, and there were inconsisten-
cies between theMethods and the Results sections. Kowalsky 1978
planned to report on ’induration’ but dropped it as an outcome
during the trial (see Characteristics of included studies). These two
studies were therefore considered to be at a high risk of reporting
bias. In Rozsos 1994, which was only reported as an abstract, re-
porting bias was unclear.
Other potential sources of bias
Only Rathbun 2012 included participants consecutively, whereas
in all other studies it was unclear if participants were consecutively
enrolled.
Effects of interventions
No study reported on the secondary outcomes development of
suppurative phlebitis, catheter-related bloodstream infections, or
aspects related to quality of life through validated quality of life
questionnaires. Only one study reported on thrombus extension
and symptomatic VTE (Rathbun 2012).
Except for the secondary outcome local adverse events, we could
not statistically pool data because of the between-study differences
in comparisons, outcomes and type of measuring instruments. We
therefore mainly describe the effects of interventions on a trial-by-
trial basis, both below and in the Data and analyses section.
Topical treatment versus inactive control
1. Heparin gel versus placebo
Four studies compared a heparinoid gel versus placebo (Kowalsky
1978; Mehta 1975; Schedel 1977; Vilardel 1999). Although these
studies evaluated the improvement of signs and symptoms with
treatment, the heterogeneity in the measurement or reporting of
the effects precluded any pooling of the results. For all outcomes
depicted in Data and analyses related to this comparison, we
graded the quality of the evidence as low. We downgraded because
of the likely attrition bias in Vilardel 1999, the unclear allocation
concealment in Kowalsky 1978 and Schedel 1977, and impreci-
sion. We deemed imprecision to be a factor for all endpoints, as
the 95% CIs contained either the ’no effect value’ of one or values
very close to one, so we could not rule out the possibility that
topical treatment is associated with trivial effects.
In Vilardel 1999 signs and symptoms of superficial throm-
bophlebitis resolved at the end of follow-up (day 7) in 27 of 61
(44%) participants receiving heparin gel versus 17 of 65 (26%) of
those receiving placebo (RR 1.69; 95% CI 1.03 to 2.78; Analysis
1.1). All 49 (39%) participants who were withdrawn from the
study and did not receive any clinical assessment were considered
as treatment failures. At the end of the follow-up period, phlebitis
was rated by the investigator as ’severe’ in 1 of 59 participants
treated with the heparin gel and in 6 of 62 treated with placebo.
The investigators judged efficacy as either ’good’ or ’moderate’ in
82% of the participants in the heparin group and in 86% of the
placebo group, and tolerability as ’good’ in 86.9% and 92.3%, re-
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spectively. One participant treated with topical heparin developed
mild urticaria.
Kowalsky 1978 reported the number of participants with a resolu-
tion of clinical signs and symptoms in the heparinoid arm versus
the placebo arm. Pain resolved in 96.2% (50 of 52) versus 76.0%
(38 of 50) (RR 1.27; 95% CI 1.07 to 1.49; Analysis 1.2), oedema
in 98.1% (51 of 52) versus 90.0% (45 of 50) (RR 1.09; 95% CI
0.99 to 1.20; Analysis 1.3), and erythema in 82.7% (43 of 52)
versus 64.0% (32 of 50) (RR 1.29; 95% CI 1.01 to 1.65; Analysis
1.4), respectively. There were no adverse events.
Mehta 1975 observed a faster relief of local symptoms and signs in
participants receiving the heparinoid cream (58 h, range 36 to 102
h) compared to placebo (126 h, range 48 to 148 h). As we were
unable to obtain or derive the standard deviation, we omit these
results from the section Data and analyses. For the same reason,
we were unable to grade the quality of evidence of this finding.
The study authors reported no local or systemic side effects.
Schedel 1977 reported the mean percentages of residual clinical
signs or symptoms at six days after start of treatment compared
to the intensity at diagnosis, which was arbitrarily set at 100%.
The pain score decreased from 100% at baseline to 3% in the
organo-heparinoid group and to 80% in the placebo group. The
oedema score decreased to 4% in the organo-heparinoid group
and to 87% in the placebo group. The erythema score decreased to
18% in the organo-heparinoid group and did not change (100%)
in the placebo group. The induration score decreased to 40%
in the organo-heparinoid group and remained at 100% in the
placebo group. There was nomeasurement of spread or statistics to
evaluate differences between groups, so we omit these results from
the section Data and analyses. One participant out of 20 (5%)
suffered from a local allergic reaction to the organo-heparinoid
ointment, leading to withdrawal from the trial (RR 3.00; 95% CI
0.13 to 69.52; Analysis 1.5).
Three studies contributed to the outcome local adverse events
(Kowalsky 1978; Schedel 1977; Vilardel 1999), but they were too
small to detect statistically significant differences (RR 3.09; 95%
CI 0.33 to 28.95; Analysis 1.5).
2. Essaven gel versus placebo
In De Sanctis 2001, a composite score based on local pain, dis-
ability and swelling decreased with Essaven gel at the end of the 4-
week treatment (MD− 9.00; 95%CI− 11.87 to− 6.13; Analysis
2.1). The authors reported the absence of treatment-related ad-
verse events in both study arms. We graded the quality of these
findings as moderate, due to unclear allocation concealment and
unclear risk of attrition bias. We did not extract the average skin
temperature, as the reported data were implausibly low (average
skin temperature as low as 24°C).
3. Phlebolan versus placebo
Nachbur 1972 reported the number of participants who re-
sponded to treatment, defining response as an evident improve-
ment of clinical signs and symptoms, and non-response as no
change or deterioration. Pain, oedema, erythema and induration
improved in 70% (16 of 23) in the phlebolan arm versus 42%
(10 of 24) in the placebo arm (RR 1.67; 95% CI 0.97 to 2.88;
Analysis 3.1). There were no adverse events. We graded the quality
of these findings as low, due to imprecision and unclear blinding
of outcome assessors.
4. Topical or oral diclofenac versus no intervention
Becherucci 2000 observed a reduction of signs and symptoms in-
tensity in 60% (24 of 40) of participants of both diclofenac groups,
compared to 20% (8 of 40) of those in the control group (for
both diclofenac groups versus control: RR 3.00; 95% CI 1.54 to
5.86; Analysis 4.1). TheMD in reduction from baseline was -5.58
(95% CI -7.38 to -3.78; Analysis 4.2) in the topical diclofenac
versus no intervention and -4.70 (95%CI -6.50 to -2.90; Analysis
4.2) in the oral diclofenac versus no intervention. Considered in-
dividually, pain, oedema, erythema and skin temperature were all
significantly reduced by topical and oral diclofenac compared to
control group (Analysis 4.3; Analysis 4.4; Analysis 4.5; Analysis
4.6). We graded the quality of these findings as moderate, due
to unclear allocation concealment and unclear blinding. Trialists
reported adverse effects for the two diclofenac groups but not for
the control group (see also comparison 7 below).
Topical treatment versus active control
Four studies compared the effects of two topical treatments
(Almenar 1993; Berrazueta 1993; Gouping 2003; Rozsos 1994),
and one study compared topical treatment versus oral treatment
(Becherucci 2000). For all outcomes listed in Data and analyses,
we graded the evidence as low to moderate due to unclear alloca-
tion concealment in all studies and unclear blinding or impreci-
sion in several others.
5. Transdermal nitroglycerine versus heparinoid gel
Almenar 1993 observed a faster clinical improvement with trans-
dermal nitroglycerin gel compared to heparinoid gel. Transdermal
nitroglycerin gel was associated with a faster resolution of pain
(50.2 h versus 72.0 h, MD -21.80 h; 95% CI -37.40 to -6.20;
Analysis 5.2), a two-fold reduction of erythema (28.8 h versus
54.6 h, MD -25.80 h; 95% CI -37.48 to 14.12; Analysis 5.3) and
of fibrous cord (58.3 h versus 84.5 h, MD -26.20 h; 95% CI -
41.87 to -10.53; MD). There was no difference in how long it
took to halve the oedema (31.2 h versus 33.0 h, MD -1.80 h;
95% CI -10.88 to 7.28; Analysis 5.5). The study authors reported
no side effects with the heparinoid gel and two cases of headache
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following the administration of transdermal nitroglycerin gel (RR
5.00; 95% CI 0.25 to 101.58; Analysis 5.6). There were no cases
of symptomatic hypotension.
In Berrazueta 1993, signs of thrombophlebitis resolved at two days
in 18 of 22 participants in the glyceryl trinitrate ointment group
and 6 of 18 of the controls. The corresponding values were 22 of
22 versus 11 of 18 at four days, and 22 of 22 versus 16 of 18 at
one week, respectively. At nine days signs of thrombophlebitis had
disappeared in all participants of both groups. At two days, the
reduction in pain was significantly higher in the glyceryl trinitrate
ointment group with an analgesic index of 84.6 ± 18 (excellent)
versus 49 ± 45% (reasonable) in the control group (P < 0.01). Two
participants in the glyceryl trinitrate ointment group experienced
headache as a side effect.
We could only pool adverse event data from Almenar 1993 and
Berrazueta 1993. The studies were too small to show any differ-
ence in average effect (RR 4.54; 95% CI 0.55 to 37.68; 140 par-
ticipants; Analysis 5.6). We graded the overall evidence as low due
to imprecision, unclear allocation concealment and potential attri-
tion bias. Although the individual study estimates were consistent
with each other, data are insufficient to exclude that the direction
of bias was the same in both studies.
6. Notoginseny cream versus heparinoid cream
In Gouping 2003, clinical signs and symptoms had resolved after
48 h in all 34 participants treated with notoginseny cream com-
pared to 26 of 31 of those on heparinoid cream (RR 0.08; 95%
CI 0.00 to 1.44; Analysis 6.1). Notoginseny was associated with
a significantly faster recovery time (MD to complete clinical reso-
lution -10.71 h; 95% CI -16.01 to -5.41; Analysis 6.2).
7. Topical versus oral Diclofenac
Becherucci 2000 is also partly described above in comparison 4.
In this study, the authors observed a 60% (24 of 40) reduction
of signs and symptoms intensity in participants from both the
topical and oral diclofenac groups. There was no difference in
mean reduction of overall symptom severity from baseline (RR -
0.88; 95% CI -2.25 to 0.49; Analysis 7.2) nor in reduction of
individual signs and symptoms such as in pain, oedema, erythema
and skin temperature considered individually (see Analysis 7.3;
Analysis 7.4; Analysis 7.5; Analysis 7.6). Reported adverse effects
for topical and oral diclofenac groups included headache (9 and
5 participants, respectively), epigastralgia (4 and 17 participants),
nausea (6 and 16 participants), and local pruritus (5 and 2 partic-
ipants). As the studies did not report information at the patient
level, we omit these results in the Data and analyses.
8. Pentosan polysulphate sodium ointment versus
mucopolysaccharide ointment
Rozsos 1994 reported that both polysulphate sodium ointment
and mucopolysaccharide ointment had equivalent efficacy, with
faster symptom reductionwith the pentosan polysulphate sodium.
Neither study reported adverse effects, and both topical treatments
werewell tolerated.None of these results are depicted in the section
Data and analyses.
Oral or parenteral treatment versus any control
See description of Becherucci 2000, which evaluated oral di-
clofenac, in comparisons 4 and 7 above.
9. Defibrotide versus no intervention
In Seccia 1989, clinical signs and symptoms of inflammation re-
solved completely within 4.8 days in the group receiving defi-
brotide versus 10.5 days in the control group. We omitted these
results fromData and analyses because we were unable to obtain or
derive the standard deviation for these results. The studies did not
report changes in other clinical signs and symptoms separately for
participants with acute thrombophlebitis of the upper extremities.
10. Dalteparin versus ibuprofen
Rathbun 2012 reported no thrombus extension or symptomatic
VTE in any participant randomised to dalteparin or ibuprofen.
There were no cases of clinically overt bleeding. We graded the
evidence to be of low quality due to imprecision. The improve-
ment of pain or adverse effects were not reported separately for
the group of participants with superficial thrombophlebitis of the
upper extremities. None of these results are depicted in the section
Data and analyses.
D I S C U S S I O N
Summary of main results
A number of topical treatments, including heparinoid or di-
clofenac gels, appeared to significantly reduce the intensity of clin-
ical signs and symptoms and achieve higher complete resolution
relative to placebo or no intervention. In one study, both topi-
cal and oral diclofenac were more effective than no intervention
in improving the clinical signs and symptoms, whereas there was
no apparent difference between the topical and oral application
(Becherucci 2000). No thrombus extension or symptomatic VTE
were observed with oral non-steroidal anti-inflammatory drugs or
low-molecular-weight heparin, but the lownumber of participants
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included limits any conclusion (Rathbun 2012). Defibrotide was
associated with a faster recovery of inflammatory signs relative to
no defibrotide, although these findings come from only 15 partici-
pants receiving extensive background therapy, which included an-
timicrobial, anti-inflammatory and mechanical treatments (Seccia
1989). No study evaluated the use of ice or the application of
cold or hot bandages, and none reported on the development of
suppurative phlebitis, catheter-related bloodstream infections, or
aspects related to quality of life through validated questionnaires.
Although several trials reported on adverse events in topical hep-
arinoid creams, Essaven gel or phlebolan versus control, the trials
were underpowered to adequately measure any differences across
treatmentmodalities (Almenar 1993; Berrazueta 1993; De Sanctis
2001; Kowalsky 1978; Nachbur 1972; Schedel 1977; Vilardel
1999). While no data were available to evaluate the risk of adverse
events in participants on either topical or oral diclofenac relative
to no treatment, the local and systemic side effects appeared to
occur at a high rate in the diclofenac groups (Becherucci 2000).
No safety data were available for notoginseny creams nor for the
parenteral low-molecular-weight heparin or defibrotide.
Quality of the evidence
Risk of bias assessment of individual trials
The methodological quality of the included studies was generally
low, although a proper assessmentwas hampered by poor reporting
(Figure 3). As an example, bias related to the random sequence
generation or allocation concealment were unclear in most of the
studies. Although we considered the risk of selective reporting bias
adequate in 10 (77%) studies, the included trials rarely addressed
relevant outcomes such as thrombus extension or symptomatic
VTE, and only about half considered adverse effects.We could not
evaluate bias related to small study size, such as publication biases.
Overall data came from 13 studies for a total of 917 participants,
where half of them had less than 50 participants and the number
per arm ranged from fewer than 10 to nomore than 60. Therefore,
both the effects observed and the lack of difference between the
groups may represent a true effect or simply chance given the
small number of RCTs, participants and events as reflected by the
very wide confidence intervals around the observed measures of
effect.Due to the scarce evidence andpoor reporting, no sensitivity
analyses according to themethodological quality of the trials could
be conducted.
Grading of the overall body of evidence
We graded the overall body of evidence as low to moderate, due
to the unclear allocation concealment, unclear blinding or impre-
cision. Due to the absence of negative results in placebo- or no
intervention-controlled studies and the unclear or high risk of bias
observed in individual trials, we judged the overall evidence for
effectiveness as low (at best), meaning that further research is very
likely to have an important impact on our confidence in the esti-
mate of effect and is likely to change the estimate.
Potential biases in the review process
We followed a systematic approach to searching, study selection
and data extraction as described in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011). It is unlikely
that we failed to identify relevant trials, but we acknowledge that
we were unable to fully evaluate two studies awaiting classification
because of language issues and the lack of author contact details
(Xiao 2004; Xu 2001). It is unlikely that the general conclusions
of the review would be influenced by the findings of these two
relatively small studies.
The fact that two independent assessors (MDN, FP or AWSR)
performed the data extraction minimised possible mistakes in this
process. As previously noted, quality assessment may be relatively
subjective and open for different interpretations, especially where
the quality of reporting is poor (Di Nisio 2013). To help readers
formulate their own judgments over the bias items, we inserted
quotations and the arguments on which we based our decisions,
as suggested by Cochrane (Higgins 2011).
Agreements and disagreements with other
studies or reviews
The 2008 guidelines of the American College of Chest Physicians
summarised the evidence about the treatment of superficial throm-
bophlebitis of the upper extremities (Kearon 2008). The guide-
line authors suggested treatment with either an oral anti-inflam-
matory drug, topical diclofenac gel, or heparin gel until resolution
of symptoms or for up to two weeks. Kearon 2008 included only
3 of the 13 RCTs considered in the present review (Becherucci
2000; De Sanctis 2001; Vilardel 1999), although they also in-
cluded a fourth study that covered superficial thrombophlebitis of
both lower and upper extremities (Bergqvist 1990). Even though
the present work has data available from 10 additional RCTs, the
evidence is still insufficient to draw conclusions regarding the ef-
ficacy and safety of topical, oral or parenteral)medical therapy for
superficial thrombophlebitis of the upper extremity.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The evidence about the treatment of acute infusion superficial
thrombophlebitis is limited and of low quality. Data appear too
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preliminary to assess the effectiveness and safety of topical treat-
ments, systemic anticoagulation or oral non-steroidal anti-inflam-
matory drugs.
Implications for research
The effect of treatment in preventing complications such as suppu-
rative superficial thrombophlebitis, catheter-related bloodstream
infections, and the effects, if any, on the underlying thrombosis
remain unknown. To demonstrate benefit of any of the evaluated
treatments, future trials should best prespecify subgroups or define
a more homogeneous patient population, and consider stratifying
participants based on relevant risk factors such as type of catheters
or duration of catheter use. Standardisation of background ther-
apy and definitions of critical and patient-relevant endpoints are
additional points of attention. For the latter, it will be important to
involve patient representatives. Such studies may evaluate whether
the addition of systemic anticoagulation to topical treatment may
confer protection against the thrombotic complications without
increasing the rate of bleeding. Whether lower doses or different
types of non-steroidal anti-inflammatory drugs can achieve clini-
cal improvements while maintaining a safe profile requires further
evaluation.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Almenar 1993
Methods Prospective, randomised study
Setting: hospital
Participants Inpatients (n = 100) with superficial phlebitis caused by endovenous catheters. Phlebitis
was “diagnosed [clinically] by the presence of pain, erythema, oedema, and fibrous cord
in area around the catheter.” Trialists did not report whether ultrasonography was used
to confirm the presence of vein thrombosis
Sex: 73/100 (73%) males
Mean age: 67.3 years (range 28 to 89 years)
Interventions Intervention A: transdermal nitroglycerine gel 2% (2 cm2 once daily)
Intervention B: heparinoid gel (sulphuric polyholoside ester sodium salt) applied tree
times a day
Study treatment was given for 6 d
The catheter was removed in all participants
Outcomes • Time for the disappearance of pain
• Time to reduction of erythema by half
• Time to reduction of oedema by half
• Time to reduction of induration (fibrous cord) by half
Clinical evaluation was performed every 4 h for 6 d
Notes Funding: not reported
Disclosure of potential conflicts of interest: not reported and no COI forms available
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of random sequence generation
only reported as occurring “according to a
randomisation order” (our translation)
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
22Treatment for superficial infusion thrombophlebitis of the upper extremity (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Almenar 1993 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk There were apparently no participants lost
to follow-up, as Table 1 in Almenar 1993
reports outcome for all participants initially
included
Selective reporting (reporting bias) Low risk Authors reported all outcomes from the
Methods section in the Results or Discus-
sion section
Other bias Unclear risk Unclear if participants were consecutively
included
Becherucci 2000
Methods Randomised, 3-arm controlled study
Setting: hospital
Participants Inpatients (n = 120) with superficial infusion thrombophlebitis defined clinically as the
presence of signs and symptoms of inflammation on and around the cannulated vein
Sex: 70/120 (58%) males
Mean age: 66.8 ± 13.5 years in the control group; 57.6 ± 17.2 years in the topical
diclofenac group; 51.9 ± 17.3 years in the oral diclofenac group
Interventions Intervention A: diclofenac topical gel 1% applied three times daily for 48 h
Intervention B: diclofenac: 75 mg twice a day orally for 48 h
Control: no intervention
Outcomes • Pain measured on a 10 cm VAS scale; erythema, oedema and warmth evaluated
through a seemingly self constructed scale ranging from 2 to 10. Measurements at
entry and 48 h later. These were totaled in the Results section as well, where we
assumed that the range of the combined scale was from 6 to 30. Treatment response
defined as a reduction of the intensity of clinical signs and symptoms by at least 30%
• Adverse effects
Notes Funding: not reported
Disclosure of potential conflicts of interest: not reported and no COI forms available
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Sequence of random numbers. Quote:
“una secuencia de 120 dígitos generados al
azar.”
Allocation concealment (selection bias) Unclear risk Not reported
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Becherucci 2000 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported. Quote: “Las variables inten-
sidad de la TFSI, rubor, tumor, calor y do-
lor fueron comparadas en función de los
promedios de las diferencias registradas en-
tre T2 y T0.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk No participants lost to follow-up. Quote:
“No se registraron pérdidas de pacientes
debido al corto período de observación de
cada caso”
Selective reporting (reporting bias) Low risk Trialists reported all outcomes from the
Methods section in the Results or Discus-
sion sections
Other bias Unclear risk Unclear if participants were consecutively
included
Berrazueta 1993
Methods Prospective, double blind, randomised study
Setting: hospital
Participants Patients (n = 40) with thrombophlebitis of a superficial forearm vein developed during
a therapeutic venous infusion. Quote: “Thrombophlebitis was defined as the presence
of two or more of the following signs: pain, local warmth, erythema, local oedema and/
or palpable venous cord . . . The severity of signs allowed thrombophlebitis to be graded
into five stages as follows:
• Grade I: pain, without other inflammatory signs
• Grade II: pain with erythema or swelling
• Grade III: pain, erythema, oedema and a palpable venous cord extending less than
5 cm
• Grade IV, all signs of Grade III in a extension of more than 5 cm with perivein
induration
• Grade V adds frank vein thrombosis with or without suppuration
Grade I thrombophlebitis was rejected for study.”
Trialist do not report the use of ultrasonography to confirm the presence of vein throm-
bosis
Sex: 20/40 (50%) males
Mean age: 60.5 ± 19.4 years
Interventions Intervention A: transdermal glyceryl trinitrate (GTN) ointment 2% gel solution at a
daily dose of 12 mg (2 cm2), applied gently without massage along the surface of the
swelling
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Berrazueta 1993 (Continued)
Intervention B: ointment of heparinoid substance (sulphuric polyholoside ester (SPE)
sodium salt)
Treatment duration not reported
Outcomes • Pain assessed with an analogue scale. The authors calculated an analgesic index
and results were considered ’excellent’ when the index was over 75%, ’good’ between
75 and 50%, ’reasonable’ between 49 and 25%, and ’bad’ when lower than 25%
• Signs of erythema, swelling, palpable venous cord, and perivein induration graded
into 5 stages
• Number of days required for complete disappearance of symptoms
Outcomes assessed every 24 hours until complete healing of thrombophlebitis
Notes Funding: This study was supported by a grant of the R Areces Foundation, Madrid,
Spain
Disclosure of potential conflicts of interest: not reported and no COI forms available
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of random sequence generation
not reported. Quote: “randomised study”
Allocation concealment (selection bias) Unclear risk Method of allocation concealment not re-
ported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Double blind study”.Quote: “The control
group was treated with SPE ointment of
identical physical characteristics to those of
the GTN ointment.” Blinding of treating
personnel not explicitly reported
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “The assessment was made blindly
by the same clinical investigator in each case
every 24 hours after ointment application.
”
Incomplete outcome data (attrition bias)
All outcomes
High risk 7 of the 47 (15%) participants initially ad-
mitted to the study were excluded. Thus,
the study population consisted of 40 partic-
ipants. Quote: “Forty-seven patients were
admitted to this study. Of these, seven pa-
tients were excluded, three because they
were discharged from the hospital before
the last evaluation and four because the pro-
tocol was not completed.”
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Berrazueta 1993 (Continued)
Selective reporting (reporting bias) Low risk Authors reported all outcomes from the
Methods section in the Results or Discus-
sion sections
Other bias Unclear risk Unclear if participants were consecutively
included
De Sanctis 2001
Methods Randomised, placebo-controlled study
Setting: hospital
Participants Patients (n = 23) with superficial thrombophlebitis of the upper extremity (distally to the
shoulder level) developed after infusion treatment with an intravenous catheter. Limbs
evaluated by colour duplex, but it is unclear whether the superficial thrombophlebitis
was defined by the presence of thrombosis
Sex: 6/12 (50%) males in the treatment arm; 6/11 (54%) males in the placebo arm
Mean age: 58 ± 7 years in the treatment arm; 59 ± 6 years in the placebo arm
Interventions Intervention: Essaven gel (5 cm2 of gel corresponding to about 1 g of Essaven gel for
each application); number of applications per day not reported
Control: placebo
Participants received low-molecular-weight heparin (enoxaparin sodium 0.1 mL/10 kg
of body weight once daily) for 4 weeks
Outcomes Average decrease in skin temperature of the affected area after 4 weeks of treatment
Analogue symptomatic score (ranging from 0 to 30) based on 3 signs/symptoms: pain,
disability and swelling, each graded from 0 (normal) to 10 (unbearable symptom/sign)
Outcomes assessed after 4 weeks
Notes Funding: none reported
Disclosure of potential conflicts of interest: not reported and no COI forms available
Gianni Belcaro was erased from the UK medical register in June 2007 for ’misconduct’,
which seems to have been that he included as co-authors on his papers people who were
not involved in the research. The GMC report did not suggest that data were falsified (
http://webcache.gmc-uk.org/minutesfiles/3313.HTML).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of sequence generation not re-
ported. Quote: “The randomization pro-
cess was controlled by an external statisti-
cian”
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De Sanctis 2001 (Continued)
Allocation concealment (selection bias) Unclear risk Quote: “Sealed envelopes were opened at
the end of evaluation of all subjects”. Not
clear if the envelopes were consecutively
numbered and opaque and whether these
were actually used to assign the treatment,
as they were opened at the end of evalu-
ation rather than at the time of randomi-
sation. The use of an external statistician
likely refers to central randomisation, but
the applied methods remain unclear
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double blind study. Quote: “Operators
were unaware of the content of the tube”
and “Placebo comparable to EG was used
(Aventis Pharma, Milan, Italy)”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Not explicitly reported, but likely blinded
as treatment assignment was revealed af-
ter outcome assessment.Quote: “Sealed en-
velopes were opened at the end of evalua-
tion of all subjects”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The number of randomised participants is
not explicitly reported. It remains unclear if
all participants randomised were evaluated
and included in the analysis
Selective reporting (reporting bias) Low risk Authors reported all outcomes from the
Methods section in the Results or Discus-
sion sections
Other bias Unclear risk Unclear if participants were consecutively
included
Gouping 2003
Methods Randomised study
Setting: hospital
Participants Patients (n = 65) with postinfusion superficial thrombophlebitis of the forearm, diag-
nosed clinically by trained nurses; trialists did not report on use of ultrasonography to
verify presence of the thrombus
Sex: 32/65 (49%) males
Age range: 4 to 90 years
Interventions Intervention A: notoginseny cream, a topical Chinese medicine containing safflower,
notoginseng, shiny-leaf prickly ash, and rhubarb
Intervention B: heparinoid cream (Hirudoid Cream, Luitpold Pharma, Munich, Ger-
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Gouping 2003 (Continued)
many)
Both topical study treatments were applied every 4 h starting as soon as the phlebitis was
diagnosed and continued until the signs and symptoms had disappeared
Outcomes Participants’ conditions and level of pain. Quote: “The four infusion nurses trained in
phlebitis assessment monitored the participants’ conditions and obtained feedback on
their level of pain”
The Methods section does not describe how these outcomes were evaluated
Notes Funding: none reported
Disclosure of potential conflicts of interest: not reported and no COI forms available
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of sequence generation not reported.
Quote: “The 65 patients were divided randomly
into two groups.”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk It is likely an open study. Study personnel was
not blinded as different dressing procedures were
used for the two topical study treatments. Quote:
“In cases where Hirudoid cream was applied, a
cotton swab was used after the cannula had been
removed, but no dressing was applied to the site
after the cream was applied”. It is unclear if par-
ticipants were blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It is not reported whether the outcome assess-
ment was blinded. Quote: “The four infusion
nurses trained in phlebitis assessment monitored
the patients’ conditions and obtained feedback
on their level of pain”
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants randomised were analysed
Selective reporting (reporting bias) Unclear risk Neither the Abstract, Introduction nor theMeth-
ods sections describe outcomes explicitly, and the
focus of the report is unclear; no protocol or trial
registration was available
Other bias Unclear risk Unclear if participants were consecutively in-
cluded
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Kowalsky 1978
Methods Prospective double blind randomised study
Setting: hospital
Participants Female inpatients (n = 102) with superficial thrombophlebitis after gynaecological oper-
ation caused by endovenous catheters. The diagnosis of phlebitis was clinical. 52 partici-
pants were allocated to the intervention and 50 participants were allocated to the control
Sex: 0 males
Mean age: 48.9 years (range 22 to 79) in the intervention group; 48.2 (15 to 77) in the
control group
Interventions Intervention: 40,000 IU organo-heparinoid per 100 g ointment (Hirudoid 40,000),
topical application
Control: topical placebo ointment
Study treatments were given for 10 d
Outcomes Proportion of the decrease of pressure pain, oedema and erythema after 10 d; severity of
symptoms was graded from 0 to 3, with 0 standing for no symptoms and 3 for severe
irritation; clinical evaluation was performed twice per day for 10 d
Notes Funding: not reported
Disclosure of potential conflicts of interest: not reported and no COI forms available
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Use of 440 numbered tubes, 220 with ac-
tive and 220 with placebo ointment. As
each patient received 4 tubes, there were
110 unique numbers provided to the 440
tubes. The randomisation code was opened
after the end of trial. It was not reported
who allocated the packages to the partic-
ipants, nor was it clear if the coding was
consecutive. As it was not reported whether
the tubes were identical in appearance, we
judged unclear risk of bias
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double blind study. Participants were ex-
plicitly reported to be blinded to study
treatment. The active and placebo oint-
ments were reported to be identical in
colour and consistency. It was not reported
if the tubes were identical as well. Blinding
of treating personnel was not explicitly re-
ported
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Kowalsky 1978 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes were assessed jointly by the par-
ticipant and the physician assessing the out-
come, who were both explicitly reported to
be blinded to study treatment
Incomplete outcome data (attrition bias)
All outcomes
Low risk It appears that the study included all ran-
domised participants in the data analyses
Selective reporting (reporting bias) High risk Induration was planned as an outcome but
not reported. The authors assumed that the
follow-up duration of 10 d was too short
to observe a decrease of induration as a re-
sponse to the therapy. At the trial level, we
judge this as high risk of bias. For the out-
comes pain, swelling and redness, it likely
does not introduce any bias
Other bias Unclear risk Unclear if participants were consecutively
included
Mehta 1975
Methods Prospective, double blind, randomised trial
Setting: hospital
Participants Inpatients (n = 100) in surgical wards who developed superficial thrombophlebitis after
continuous intravenous infusion of normal saline, dextrose saline, blood, or other fluids.
Thrombophlebitis was diagnosed clinically “when a tender palpable cord or a red flare
developed over the vein after stopping the infusion.” 125I-labelled fibrinogen test used
for detecting the presence of thrombi. Quote: “The original difference in radioactivity
between this site and the corresponding area on the opposite (unaffected) limb was as-
sumed to represent the total radioactivity contained in the thrombus and locally accu-
mulated inflammatory exudate.”
Sex: 39/50 (78%) males in the treatment arm; 34/50 (68%) males in the placebo arm
Mean age: 44.9 years (range 17 to 72) in the treatment arm; 56.3 years (range 35 to 83)
in the placebo arm
Interventions Intervention: heparinoid ointment (Hirudoid)
Control: placebo cream
Study treatment was applied to the area of redness and tenderness, and this was followed
by firm bandaging. Treatment was repeated daily for at least 5 d and continued thereafter
if symptoms persisted
Outcomes Time to relief of local symptoms and signs and the rate of local decline in radioactivity
(not extracted)
Outcomes assessed every every day for 5 days.
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Mehta 1975 (Continued)
Notes Funding: financial support from the King’s College Hospital Research Trust; Luitpold-
Werk (Munich) supplied Hirudoid and placebo cream
Disclosure of potential conflicts of interest: not reported and no COI forms available
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of sequence generation not re-
ported. Quote: “treatment schedules dis-
tributed in random order”
Allocation concealment (selection bias) Low risk Quote: “One hundred envelopes were pre-
pared, sealed, and numbered in sequence,
each containing one of two treatment
schedules distributed in random order. As
each patient was admitted to the trial his
treatment was selected by opening the next
envelope, which indicated whether the pa-
tient was to receive the contents of a green
or a red tube.” Opacity of envelopes not
reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double blind study with colour-coded
tubes. Quote: “After completion of the trial
the red tubes were found to contain the ac-
tive, heparinoid compound and the green
tubes the placebo cream.” We judged low
risk of bias as an attempt to blinding was
made (see review protocol), but acknowl-
edge that the blinding is suboptimal, as
the evident difference in colour enhances
the chance that personnel and even partic-
ipants understand which product is the ac-
tive ointment
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of outcome assessment not re-
ported explicitly, but this was likely given
that treatment assignment was blinded and
disclosed at the end of the study. Quote:
“After completion of the trial the red tubes
were found to contain the active, hepari-
noid compound and the green tubes the
placebo cream.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised participants evaluated and
included in the analysis. Quote: “All pa-
tients successfully completed a full course
of treatment and no local or systemic side
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Mehta 1975 (Continued)
effects were observed.”
Selective reporting (reporting bias) Low risk Authors reported all outcomes from the
Methods section in the Results or Discus-
sion sections
Other bias Unclear risk Unclear if participants were consecutively
included
Nachbur 1972
Methods Prospective double blind randomised study
Setting: hospital
Participants Inpatients (n = 48) with superficial thrombophlebitis caused by endovenous catheters.
The diagnosis of phlebitis was clinical. 24 participants were allocated to the intervention
and 24 participants were allocated to the control
Age and sex not reported
Interventions Intervention: phlebolan spray containing diphenylbutazone 5%, prednisolone 0.5%,
sodium rutin sulphate 0.2%, topical application three times per day
Control: placebo spray, topical application three times per day
Study treatment was given for 5 d
Outcomes Proportion of treatment responders with evident improvement of skin temperature,
erythema, induration, pain and oedema after 5 d; severity of symptoms was graded from
for pain and oedema as follows: 0 standing for no symptoms, + for light and ++ for
strong irritation
Notes Funding: not reported
Disclosure of potential conflicts of interest: not reported and no COI forms available
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of random sequence generation
not reported
Allocation concealment (selection bias) Low risk Use of coded packages that were identical
in appearance. Trialists did not report who
allocated the packages to the participants,
nor was it clear if the coding was consecu-
tive. As the packages were identical in ap-
pearance, we judged low risk of bias
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Nachbur 1972 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double blind study using coded packages.
Trialists did not explicitly report who was
blind or whether the substances were iden-
tical in appearance
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double blind study, but outcome assessors
were not explicitly reported to be blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk The data of one patient from the interven-
tion group (1 out of 24; 4%) was not anal-
ysed because the mode of application did
not comply with the protocol
Selective reporting (reporting bias) Low risk The single outcome reported in the Meth-
ods sectionwas addressed in theResults sec-
tion
Other bias Unclear risk Unclear if participants were consecutively
included
Rathbun 2012
Methods Randomised, controlled, double blind, double dummy trial
Setting: inpatients and outpatients
Participants Consecutive inpatients and outpatients with superficial thrombophlebitis of the lower
(n = 57) or upper (n = 15) extremities in the absence of a current intravenous (IV)
catheter. Presence of the thrombus was objectively tested using ultrasonography. Only
the participants with superficial thrombophlebitis of the upper extremity were included
in this review
Sex and age are not reported separately for the group with superficial thrombophlebitis
of the upper extremity
Interventions Intervention A: Dalteparin (200 IU/kg sc at presentation followed by 10,000 IU sc
daily for
an additional 6 d) plus placebo given orally three times daily for 7 d
Intervention B: Ibuprofen 800 mg given orally three times daily for 7 d plus placebo
injections given daily for 7 d
In case the symptoms of superficial thrombophlebitis were not resolved at days 7-9, the
patient received an additional 7 d of the blinded therapy provided there was no thrombus
extension
Outcomes Primary outcome: extension of thrombus or new symptomatic VTE during the 14-day
and 3-month follow-up period
Secondary outcomes: reduction in pain; major, minor and trivial bleeding; thrombo-
cytopenia
Pain severity was evaluated at presentation and during the 14-day treatment period using
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Rathbun 2012 (Continued)
the 11-point Box Pain scale
Follow-up visits were scheduled at days 7-9, 14-16 and at 1 and 3 months. Ultrasonog-
raphy was repeated on days 7-9 and 14-16 to verify thrombus extension
Notes Funding: The authors acknowledged the support of the University of OklahomaGeneral
Clinical Research Center grant M01 RR14467 from the National Center for Research
Resources,National Institutes ofHealth, andPzer Inc. for provision of dalteparin sodium,
ibuprofen and nurse personnel salary support
Disclosure of potential conflicts of interest: The authors stated that they had no conflict
of interest
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomizationwas performedus-
ing balanced randomization blocks of four
each consisting of equal numbers”
Allocation concealment (selection bias) Low risk Quote: “Randomizationwas performedus-
ing balanced randomization blocks of four
each consisting of equal numbers” and
“Randomization of patient to treatment
group was performed by the investigational
medication pharmacist within 24 h of pre-
senting with a confirmed diagnosis of su-
percial thrombophlebitis.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double blind study. Quote: “The patient,
research assistant and principal investigator
were blinded to the treatment group.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Trialists do not report if outcome assess-
ment was blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Trialists do not report if all participants in-
cluded were followed up to 3 months and
included in the analysis
Selective reporting (reporting bias) Low risk Authors reported all outcomes from the
Methods section in the Results or Discus-
sion sections
Other bias Low risk No apparent other sources of bias. Partici-
pants consecutively included
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Rozsos 1994
Methods Randomised double blind trial
Setting: hospital
Participants Adult patients (n = 110) with acute infusion thrombophlebitis in one arm. Age and sex
not reported. It is not reported whether thrombophlebitis was defined by the presence
of a thrombus nor if ultrasonography was performed
Interventions Intervention A: pentosan polysulphate sodium ointment 0.5%
Intervention B: mucopolysaccharide ointment 0.445%
Study medication was applied three times daily
Outcomes • Symptoms (induration, swelling, erythema, temperature, pain) severity combined
into a score with a 5-stage scale; symptoms assessed daily
• Radioactivity over the inflamed veins on day 1, 3 and 7 of the treatment period
measured by 125I-fibrinogen test
Notes Funding: none reported.
Disclosure of potential conflicts of interest: not reported and no COI forms available
Study reported in abstract form only.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Trialists report the study to be double blind,
but not the method of blinding nor who
was blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear whether all participants ran-
domised were included in the analysis;
study only available as an abstract
Selective reporting (reporting bias) Unclear risk Unclear whether all outcomes were pre-
sented; no protocol or Methods section
available
Other bias Unclear risk Unclear if participants were consecutively
included
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Schedel 1977
Methods Prospective double blind randomised study
Setting: hospital
Participants Inpatients (n = 40) with superficial thrombophlebitis after various operations. The di-
agnosis of phlebitis was clinical. 20 participants were allocated to the intervention and
20 participants were allocated to the control
Sex: 8/20 (40%) males in the treatment arm; 7/20 (35%) males in the placebo arm
Mean age: 59.7 years (range 34 to 90) in the intervention group; 60.6 years (18 to 90)
in the control group
Interventions Intervention: organo-heparinoid, topical application twice per day
Control: placebo ointment, topical application twice per day
Study treatment was given for 6 d
Outcomes • Primary outcome: result of a 125I fibrinogen scan of the affected side compared to
the unaffected side (not extracted)
• Secondary outcomes: proportion of the remaining pain, oedema, induration and
erythema after 6 d. Severity of symptoms was graded from 0 to 4: 0 standing for no
symptoms, 1 for light, 2 for medium, 3 for strong, and 4 for very strong irritation
Outcomes assessed at 6 days
Notes Funding: not reported
Disclosure of potential conflicts of interest: not reported and no COI forms available
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of random sequence generation
not reported
Allocation concealment (selection bias) Unclear risk Use of colour-coded ointment described;
method of allocation concealment not re-
ported in sufficient detail to allow a judg-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double blind study with colour-coded
ointment. In line with our protocol we
judged low risk of bias as there was an
attempt to blind. We acknowledge that
colour coding may have increased the
awareness of personnel and even partici-
pants to distinguish the active and placebo
ointments
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double blind study; although it is not
explicitly reported if outcome assessors
(the physician for oedema, induration and
erythema; the participant for pain) were
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Schedel 1977 (Continued)
blinded, we deduce that they were, as the
treatment assignment was reported to be
disclosed at the end of the study. Quote:
“After completion of the outcome assess-
ments, the code was opened” (our transla-
tion)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 19 out of 20 (95%) randomised partic-
ipants were analysed in the experimental
group, 20 out of 20 (100%) were analysed
in the control group
Selective reporting (reporting bias) Low risk Authors reported all outcomes from the
Methods section in the Results or Discus-
sion sections
Other bias Unclear risk Unclear if participants were consecutively
included
Seccia 1989
Methods Randomised, two-arm open study
Setting: inpatients and outpatients
Participants Outpatients and inpatients with superficial thrombophlebitis of the lower (n = 125) and
upper extremities (n = 15). Trialists did not report whether thrombophlebitis was defined
by the presence of a thrombus
Sex and age not reported
Interventions Within 72 h of symptoms onset:
Intervention A (n = 7): standard treatment B plus defibrotide 800 mg/d IM for 4 d
followed by 400 mg/d IM until clinical resolution
Intervention B (n = 8): standard treatment consisting of antimicrobic therapy (bacampi-
cillin 800 mg/d for 48 h) plus diclofenac 100 mg/d, topical desoxyribonuclease and
elastic compression until clinical resolution
Outcomes • Variation of signs (body and local temperature, redness, oedema, satellite
adenopathy)
• Pain
• Laboratory parameters (leucocytosis)
Indicators evaluated before treatment start and subsequently every 3 d by the medical
study personnel and recorded daily by the patient
Periodic checks performed by Doppler ultrasonography to exclude the extension into
the deep vein system
Notes Funding: none reported
Disclosure of potential conflicts of interest: not reported and no COI forms available
The original study relates to 140 participants. We did not report the study details relating
to the 125 participant with lower extremity phlebitis. The study stratified by the time
37Treatment for superficial infusion thrombophlebitis of the upper extremity (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Seccia 1989 (Continued)
to onset of symptoms, but this related to those with lower extremity phlebitis only
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of random sequence generation
not reported. Participants were first divided
based on the time elapsed from onset of
symptoms and subsequently randomised to
study treatment
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and personnel were not
blinded to study treatment. Quote: “La
rilevazione è stata effettuata da personale
medico a intervalli di 3 giorni e regis-
trata quotidianamente da parte del paziente
stesso”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Outcomes were assessed by participants
and personnel who were not blinded to
study treatment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 3 participants within the defibrotide group
were excluded from the study after they had
developed allergic reactions to the drug in
the first 24-48 h of treatment. It is not re-
ported if these 3 participants belonged to
the group of 15 participants with throm-
bophlebitis of the upper extremity (per-
centage of participants analysed from the
upper extremity subgroup may be between
80% and 100% of the total). Quote: “3
casi di pazienti tolti dallo studio in fase del
tutto precoce”
Selective reporting (reporting bias) Low risk For the entire group including lower ex-
tremity phlebitis, authors reported all out-
comes from theMethods section in the Re-
sults or Discussion section. As lower ex-
tremity was not the focus of the study, we
judged that therewas no indication for high
risk of bias
Other bias Unclear risk Unclear if participants were consecutively
included
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Vilardel 1999
Methods Randomised, placebo-controlled, double blind study
Setting: hospital
Participants Inpatients (n = 132) over 18 years with acute superficial phlebitis secondary to indwelling
IV catheter
Sex: 24/61 (39%) males in the treatment arm; 26/65 (40%) males in the placebo arm
Age not reported
Not reported whether thrombophlebitis was defined by the presence of a thrombus nor
if ultrasonography was performed
Interventions Intervention: topical sodium bovine heparin as gel preparation (containing 1000 IU/g
of heparin)
Control: placebo
Topical heparin or placebo applied three times daily until clinical healing or for a maxi-
mum of 7 d
Application of other anti-inflammatory topical preparations not allowed during the
study. Anticoagulants were administered to 6 participants in the intervention group and
1 in the control group
Outcomes • Disappearance of the symptoms and signs of superficial phlebitis
• Investigator’s global impression
• Adverse events
Clinical evaluation of the superficial phlebitis was done by the nurse personnel every 24
h until healing or for a maximum follow-up of 7 d
Notes Funding: Laboratorios Menarini, S.A. (Barcelona) provided the product samples and
financial support for the conduct of the study
Disclosure of potential conflicts of interest: not reported and no COI forms available
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The assignment schedule was gen-
erated at Institut Català de Farmacologia
by a computer random number generator”
Allocation concealment (selection bias) Low risk Quote: “[S]tudy medication was supplied
to the hospital pharmacy” and “[L]abelling
was neutral and identified with the patient
inclusion number . . . For each patient, two
tubes were available . . . For each patient
the investigator received an opaque enve-
lope with the inclusion number and the
identification of the sample; codes could
only be disclosed in the case of severe ad-
verse events and at the end of the statistical
evaluation.” The authors also report that
the “inclusion sequence followed the ran-
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Vilardel 1999 (Continued)
domisation plan with two exceptions: one
in the intervention group and another one
in the control group.” Although it was not
reported whether randomisation envelopes
were sealed, we judged low risk of bias for
the overall procedure
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double blind study. Quote: “[L]abelling
was neutral and identified with the patient
inclusion number . . . For each patient, two
tubes were available . . . For each patient the
investigator received an opaque envelope
with the inclusion number and the identi-
fication of the sample; codes could only be
disclosed in the case of severe adverse events
and at the end of the statistical evaluation”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “[C]odes could only be disclosed in
the case of severe adverse events and at the
end of the statistical evaluation”
Incomplete outcome data (attrition bias)
All outcomes
High risk 6 (4.5%) participants with protocol devia-
tions (5 in the heparin and 1 in the placebo)
were excluded from the analysis. Quote:
“There were five protocol deviations in the
intervention group and one in the con-
trol group. In the intervention group, three
cases were included in the study for a sec-
ond time; additionally, in this group two
cases were identified as the same patient
treated for a few days simultaneously for
two concomitant episodes of phlebitis. In
the control group, one case corresponded
to a second superficial phlebitis in a patient
previously included in the study”
There were 49 (39%) withdrawals, 24 in
the intervention group (36.4%) and 25 in
the control group (37.9%). All these par-
ticipants were considered as treatment fail-
ures
Quote: “Sixteen patients in the interven-
tion group and18 in the control groupwere
discharged before phlebitis had healed. Five
patients in the intervention group and four
in the control group decided to withdraw
from the study.One patient in the interven-
tion group and two in the control group de-
veloped concomitant illnesses and applica-
tion of the study preparationwas discontin-
40Treatment for superficial infusion thrombophlebitis of the upper extremity (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Vilardel 1999 (Continued)
ued. One patient in the intervention group
died of liver cirrhosis, and another one de-
veloped contact urticaria. In one patient of
the control group, study medication was
insufficient due to the size of the phlebitis
lesion (29 cm). For the intention-to-treat
analysis all these cases were considered as
failures”
Selective reporting (reporting bias) Low risk Authors reported all outcomes from the
Methods section in the Results or Discus-
sion sections
Other bias Unclear risk Unclear if participants were consecutively
included
COI: conflict of interest; EG: Esseven gel; G MC: General Medical Council (UK); IM: intramuscular; IV: intravenous(ly); sc:
subcutaneously; VAS: visual analogue scale; VTE: venous thromboembolism.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bergqvist 1990 The study includes participants with superficial thrombophlebitis of the lower extremities and upper ex-
tremities and it is not possible to extract data separately for latter
Bruni 1979 The study includes participants with superficial thrombophlebitis of the lower extremities and upper ex-
tremities and it is not possible to extract data separately for latter
Cökmez 2003 Study on the prevention of superficial thrombophlebitis
D’Amico 1987 The study includes participants with vein insufficiency, post-thrombotic syndrome, and superficial throm-
bophlebitis of the lower extremities
De Tullio 1989 Participants with superficial thrombophlebitis or deep vein thrombosis of the lower extremities
Gorski 2005 Participants with superficial thrombophlebitis of the lower extremities
Marrapodi 1986 Not an RCT
Messing 1985 Study on the prevention of superficial thrombophlebitis
Nieto-Rodriguez 1992 Study on the prevention of superficial thrombophlebitis
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Nocker 1990 Participants with superficial thrombophlebitis of the lower extremities
Nocker 1991 Participants with superficial thrombophlebitis of the lower extremities
Porters 1981 The study includes participants with superficial thrombophlebitis of the lower extremities and upper ex-
tremities and it is not possible to extract data separately for latter
Pozza 1980 The study includes participants with superficial thrombophlebitis of the lower extremities and upper ex-
tremities and it is not possible to extract data separately for latter
Reid 1990 Study on the prevention of superficial thrombophlebitis
Stolle 1986 Participants with superficial thrombophlebitis of the lower extremities and only two of the upper extremities
Wright 1985 Study on the prevention of superficial thrombophlebitis
RCT: randomised controlled trial
Characteristics of studies awaiting assessment [ordered by study ID]
Xiao 2004
Methods Randomised study
Participants Chronic hepatopathy patients (n = 102) with peripheral phlebitis induced by fluid infusion
Interventions Intervention: Notoginseng alcohol for external application
Control: magnesium sulphate solution for external application
Outcomes Recovery of impaired vein
Notes Study available in Chinese. It is currently not possible to extract data from the study
Xu 2001
Methods Not reported
Participants Not reported
Interventions Not reported
Outcomes Not reported
Notes Study available in Chinese. It is currently not possible to extract data from the study
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Characteristics of ongoing studies [ordered by study ID]
CTRI/2012/05/002629
Trial name or title Prevalence of infusion related inflammation of the vein and the comparison of the effectiveness of heparinoid
application and ichthammol glycerin application on the reduction of infusion related inflammation of the
vein
Methods Unclear method of random sequence generation: “Method of generating randomization sequence: Coin toss,
Lottery, toss of dice, shuffling cards et”. Likely an open study with no allocation concealment: “Method of
allocation concealment: Not Applicable. Blinding and masking: Not Applicable”
Participants All adult patients admitted in selected adult wards who develop phlebitis of the upper limb with a visual
infusion phlebitis score of two or more as the result of intravenous therapy
Interventions Intervention A: heparinoid ointment applied in a thin layer to the skin of the affected part and its surrounding
area two times per day for 48 h
Intervention B: 30-50 mL of ichthammol glycerine applied while doing dressing on the affected site 2 times
daily for 48 h
Outcomes Efficacy of intervention at 6 weeks
Starting date 11 June 2012
Contact information Dr Punitha Ezhilarasu: punitha@cmcvellore.ac.in
Notes CTRI: http://apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2012/05/002629
CTRI/2013/12/004245
Trial name or title Comparison of the effectiveness of Ichthammol glycerine, heparinoid application and Magsulph glycerine
application on the reduction of infusion related inflammation of the vein
Methods “Method of generating randomisation sequence: computer generated randomisation; method of allocation
concealment: open list of random numbers. Blinding andmasking: participant and outcome assessor blinded”
Participants All patients admitted in Advanced Cardiac Centre, Postgraduate Institute of Medical Education and Research
(PGIMER), Chandigarh, India, who developed phlebitis with visual infusion phlebitis score of ≥ 2 as the
result of intravenous therapy
Interventions Intervention A: 3-5 mL of ichthammol glycerine used for doing dressing on the affected site two times daily
for 72 h
Intervention B: heparinoid ointment applied in a thin layer to the skin of the affected part and its surrounding
two times per day for 72 h.
Intervention C: magsulph glycerine applied in a thin layer to the skin of the affected part and its surrounding
area two times per day for 72 h
Outcomes Primary: efficacy of intervention at 6 weeks
Secondary: pharmacoeconomics of intervention at 6 weeks
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CTRI/2013/12/004245 (Continued)
Starting date 15 July 2013
Contact information Dr Bikash Medhi: drbikashus@yahoo.com
Notes CTRI: http://apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2013/12/004245
NCT00377806
Trial name or title Topical diclofenac gel in patients with superficial inflammation of the veins
Methods Randomised, double blind
Participants Patients with spontaneous or iatrogenic superficial thrombophlebitis of the upper limb
Interventions Intervention: diclofenac gel
Outcomes Primary outcome: area under the curve (AUC) of the symptom score (pain, temperature and size of erythema
along the superficial vein)
Secondary outcomes
• Patient’s global assessment of drug effect at each visit
• AUC of assessment of temperature of inflammatory area around superficial thrombophlebitis between
treatment day 1 and 5
• AUC of assessment of inflammatory area of the superficial thrombophlebitis between treatment day 1
and 5
• AUC of assessment of pain (visual analogue scale) between treatment day 1 and day 5
• Physician’s global assessment of drug effect at each visit
Starting date January 2003
Contact information Novartis Pharmaceuticals
Notes ClinicalTrials.gov identifier: NCT00377806
NCT01943006
Trial name or title Efficacy and tolerability of Hirudoid cream in prophylaxis and treatment infusion phlebitis
Methods Randomised, placebo-controlled study
Participants Inpatients receiving infusion of a complete nutritional emulsion for 3 d (Kabiven Peripheral, 1400 kcal, 1920
mL, 750 mOsmol/L, pH 5.6)
Interventions Intervention: Hirudoid cream 0.3% mucopolysaccharide polysulphate twice daily
Control: placebo
The treatment will be continued after the end of infusion for at least 7 d
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NCT01943006 (Continued)
Outcomes Primary outcome measures: number of patient developing superficial thrombophlebitis
Secondary outcome measures
• Time to develop infusion related superficial thrombophlebitis
• Change of clinical symptoms in participants who developed superficial thrombophlebitis
• Time to complete resolution of signs and symptoms in participants who developed superficial
thrombophlebitis
• Investigators’ and participants’ satisfaction
• Adverse events
• Global tolerability
Starting date This study is not yet open for participant recruitment. Verified: September 2013 by Medinova AG
Contact information Contact: Tun Myint Win, MD +66 8 1847 5696 tun.myint.win@dksh.com
Contact: Philipp Grob, PhD +41 792910960 grob.philipp@medinova.ch
Notes Sponsor: Medinova AG
ClinicalTrials.gov Identifier: NCT01943006
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D A T A A N D A N A L Y S E S
Comparison 1. Topical treatment versus inactive control: heparin gel versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Disappearance of signs and
symptoms
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
2 Pain resolution 1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
3 Oedema resolution 1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
4 Erythema resolution 1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
5 Local adverse events 3 268 Risk Ratio (IV, Random, 95% CI) 3.09 [0.33, 28.95]
5.1 Organo-heparinoid 2 142 Risk Ratio (IV, Random, 95% CI) 3.00 [0.13, 69.52]
5.2 Heparin gel 1 126 Risk Ratio (IV, Random, 95% CI) 3.19 [0.13, 76.93]
Comparison 2. Topical treatment versus inactive control: Essaven gel versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Combined score of persisting
signs/symptoms
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2 Treatment related adverse events 1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
Comparison 3. Topical treatment versus inactive control: Phlebolan versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinical response 1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
2 Adverse events 1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
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Comparison 4. Topical or oral treatment versus inactive control: topical or oral diclofenac versus no intervention
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinical response 1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
2 Reduction in symptom severity 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 Topical diclofenac 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 Oral diclofenac 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Pain reduction 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.1 Topical diclofenac 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Oral diclofenac 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Oedema reduction 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.1 Topical diclofenac 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 Oral diclofenac 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Erythema reduction 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
5.1 Topical diclofenac 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 Oral diclofenac 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Skin temperature reduction 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
6.1 Topical diclofenac 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.2 Oral diclofenac 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 5. Topical treatment versus active control: transdermal nitroglycerine versus heparinoid gel
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Disappearance of signs and
symptoms
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
2 Time (h) to pain disappearance 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3 Time (h) to halving of erythema 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
4 Time (h) to halving of fibrous
cord
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
5 Time (h) to halving of oedema 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
6 Adverse events 2 140 Risk Ratio (IV, Random, 95% CI) 4.54 [0.55, 37.68]
Comparison 6. Topical treatment versus active control: notoginseny cream versus heparinoid cream
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Persistence of signs and
symptoms at 48 h
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
2 Mean time (h) for clinical
resolution
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
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Comparison 7. Topical treatment versus active control: topical versus oral diclofenac
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinical response 1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
2 Reduction in symptom severity 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3 Pain reduction 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
4 Oedema reduction 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
5 Erythema reduction 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
6 Skin temperature reduction 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
Analysis 1.1. Comparison 1 Topical treatment versus inactive control: heparin gel versus placebo, Outcome
1 Disappearance of signs and symptoms.
Review: Treatment for superficial infusion thrombophlebitis of the upper extremity
Comparison: 1 Topical treatment versus inactive control: heparin gel versus placebo
Outcome: 1 Disappearance of signs and symptoms
Study or subgroup Heparin gel Placebo Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Vilardel 1999 27/61 17/65 1.69 [ 1.03, 2.78 ]
0.01 0.1 1 10 100
Favours placebo Favours Heparin gel
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Analysis 1.2. Comparison 1 Topical treatment versus inactive control: heparin gel versus placebo, Outcome
2 Pain resolution.
Review: Treatment for superficial infusion thrombophlebitis of the upper extremity
Comparison: 1 Topical treatment versus inactive control: heparin gel versus placebo
Outcome: 2 Pain resolution
Study or subgroup Hirudoid Placebo Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Kowalsky 1978 50/52 38/50 1.27 [ 1.07, 1.49 ]
0.1 0.2 0.5 1 2 5 10
Favours placebo Favours Hirudoid
Analysis 1.3. Comparison 1 Topical treatment versus inactive control: heparin gel versus placebo, Outcome
3 Oedema resolution.
Review: Treatment for superficial infusion thrombophlebitis of the upper extremity
Comparison: 1 Topical treatment versus inactive control: heparin gel versus placebo
Outcome: 3 Oedema resolution
Study or subgroup Hirudoid Placebo Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Kowalsky 1978 51/52 45/50 1.09 [ 0.99, 1.20 ]
0.5 0.7 1 1.5 2
Favours placebo Favours Hirudoid
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Analysis 1.4. Comparison 1 Topical treatment versus inactive control: heparin gel versus placebo, Outcome
4 Erythema resolution.
Review: Treatment for superficial infusion thrombophlebitis of the upper extremity
Comparison: 1 Topical treatment versus inactive control: heparin gel versus placebo
Outcome: 4 Erythema resolution
Study or subgroup Hirudoid Placebo Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Kowalsky 1978 43/52 32/50 1.29 [ 1.01, 1.65 ]
0.01 0.1 1 10 100
Favours placebo Favours Hirudoid
Analysis 1.5. Comparison 1 Topical treatment versus inactive control: heparin gel versus placebo, Outcome
5 Local adverse events.
Review: Treatment for superficial infusion thrombophlebitis of the upper extremity
Comparison: 1 Topical treatment versus inactive control: heparin gel versus placebo
Outcome: 5 Local adverse events
Study or subgroup Favours heparin gel Placebo Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Organo-heparinoid
Kowalsky 1978 0/52 0/50 Not estimable
Schedel 1977 1/20 0/20 50.6 % 3.00 [ 0.13, 69.52 ]
Subtotal (95% CI) 72 70 50.6 % 3.00 [ 0.13, 69.52 ]
Total events: 1 (Favours heparin gel), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
2 Heparin gel
Vilardel 1999 1/61 0/65 49.4 % 3.19 [ 0.13, 76.93 ]
Subtotal (95% CI) 61 65 49.4 % 3.19 [ 0.13, 76.93 ]
Total events: 1 (Favours heparin gel), 0 (Placebo)
Heterogeneity: not applicable
0.001 0.01 0.1 1 10 100 1000
Favours heparin gel Favours placebo
(Continued . . . )
50Treatment for superficial infusion thrombophlebitis of the upper extremity (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Favours heparin gel Placebo Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Test for overall effect: Z = 0.72 (P = 0.47)
Total (95% CI) 133 135 100.0 % 3.09 [ 0.33, 28.95 ]
Total events: 2 (Favours heparin gel), 0 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.99 (P = 0.32)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.98), I2 =0.0%
0.001 0.01 0.1 1 10 100 1000
Favours heparin gel Favours placebo
Analysis 2.1. Comparison 2 Topical treatment versus inactive control: Essaven gel versus placebo, Outcome
1 Combined score of persisting signs/symptoms.
Review: Treatment for superficial infusion thrombophlebitis of the upper extremity
Comparison: 2 Topical treatment versus inactive control: Essaven gel versus placebo
Outcome: 1 Combined score of persisting signs/symptoms
Study or subgroup Essaven Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
De Sanctis 2001 12 7 (4) 11 16 (3) -9.00 [ -11.87, -6.13 ]
-100 -50 0 50 100
Favours Essaven Favours placebo
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Analysis 2.2. Comparison 2 Topical treatment versus inactive control: Essaven gel versus placebo, Outcome
2 Treatment related adverse events.
Review: Treatment for superficial infusion thrombophlebitis of the upper extremity
Comparison: 2 Topical treatment versus inactive control: Essaven gel versus placebo
Outcome: 2 Treatment related adverse events
Study or subgroup Essaven Placebo Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
De Sanctis 2001 0/12 0/11 Not estimable
0.01 0.1 1 10 100
Favours Essaven Favours placebo
Analysis 3.1. Comparison 3 Topical treatment versus inactive control: Phlebolan versus placebo, Outcome
1 Clinical response.
Review: Treatment for superficial infusion thrombophlebitis of the upper extremity
Comparison: 3 Topical treatment versus inactive control: Phlebolan versus placebo
Outcome: 1 Clinical response
Study or subgroup Phlebolan Placebo Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Nachbur 1972 16/23 10/24 1.67 [ 0.97, 2.88 ]
0.01 0.1 1 10 100
Favours placebo Favours Phlebolan
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Analysis 3.2. Comparison 3 Topical treatment versus inactive control: Phlebolan versus placebo, Outcome
2 Adverse events.
Review: Treatment for superficial infusion thrombophlebitis of the upper extremity
Comparison: 3 Topical treatment versus inactive control: Phlebolan versus placebo
Outcome: 2 Adverse events
Study or subgroup Phlebolan Placebo Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Nachbur 1972 0/23 0/24 Not estimable
0.01 0.1 1 10 100
Favours phlebolan Favours placebo
Analysis 4.1. Comparison 4 Topical or oral treatment versus inactive control: topical or oral diclofenac
versus no intervention, Outcome 1 Clinical response.
Review: Treatment for superficial infusion thrombophlebitis of the upper extremity
Comparison: 4 Topical or oral treatment versus inactive control: topical or oral diclofenac versus no intervention
Outcome: 1 Clinical response
Study or subgroup Diclofenac No treatment Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Becherucci 2000 24/40 8/40 3.00 [ 1.54, 5.86 ]
0.01 0.1 1 10 100
Favours no treatment Favours Diclofenac
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Analysis 4.2. Comparison 4 Topical or oral treatment versus inactive control: topical or oral diclofenac
versus no intervention, Outcome 2 Reduction in symptom severity.
Review: Treatment for superficial infusion thrombophlebitis of the upper extremity
Comparison: 4 Topical or oral treatment versus inactive control: topical or oral diclofenac versus no intervention
Outcome: 2 Reduction in symptom severity
Study or subgroup Diclofenac No treatment
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Topical diclofenac
Becherucci 2000 40 -5.7 (3.13) 40 -0.12 (4.89) -5.58 [ -7.38, -3.78 ]
2 Oral diclofenac
Becherucci 2000 40 -4.82 (3.14) 40 -0.12 (4.89) -4.70 [ -6.50, -2.90 ]
-10 -5 0 5 10
Favours Diclofenac Favours no treatment
Analysis 4.3. Comparison 4 Topical or oral treatment versus inactive control: topical or oral diclofenac
versus no intervention, Outcome 3 Pain reduction.
Review: Treatment for superficial infusion thrombophlebitis of the upper extremity
Comparison: 4 Topical or oral treatment versus inactive control: topical or oral diclofenac versus no intervention
Outcome: 3 Pain reduction
Study or subgroup Diclofenac No treatment
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Topical diclofenac
Becherucci 2000 40 -2.25 (1.58) 40 0.07 (1.99) -2.32 [ -3.11, -1.53 ]
2 Oral diclofenac
Becherucci 2000 40 -2 (1.6) 40 0.07 (1.99) -2.07 [ -2.86, -1.28 ]
-10 -5 0 5 10
Favours Diclofenac Favours no treatment
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Analysis 4.4. Comparison 4 Topical or oral treatment versus inactive control: topical or oral diclofenac
versus no intervention, Outcome 4 Oedema reduction.
Review: Treatment for superficial infusion thrombophlebitis of the upper extremity
Comparison: 4 Topical or oral treatment versus inactive control: topical or oral diclofenac versus no intervention
Outcome: 4 Oedema reduction
Study or subgroup Diclofenac No treatment
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Topical diclofenac
Becherucci 2000 40 -2.05 (1.23) 40 0.01 (1.87) -2.06 [ -2.75, -1.37 ]
2 Oral diclofenac
Becherucci 2000 40 -1.72 (1.48) 40 0.01 (1.87) -1.73 [ -2.47, -0.99 ]
-10 -5 0 5 10
Favours Diclofenac Favours no treatment
Analysis 4.5. Comparison 4 Topical or oral treatment versus inactive control: topical or oral diclofenac
versus no intervention, Outcome 5 Erythema reduction.
Review: Treatment for superficial infusion thrombophlebitis of the upper extremity
Comparison: 4 Topical or oral treatment versus inactive control: topical or oral diclofenac versus no intervention
Outcome: 5 Erythema reduction
Study or subgroup Diclofenac No treatment
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Topical diclofenac
Becherucci 2000 40 -2.77 (1.84) 40 0.16 (2.5) -2.93 [ -3.89, -1.97 ]
2 Oral diclofenac
Becherucci 2000 40 -2.2 (1.36) 40 0.16 (2.5) -2.36 [ -3.24, -1.48 ]
-10 -5 0 5 10
Favours Diclofenac Favours no treatment
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Analysis 4.6. Comparison 4 Topical or oral treatment versus inactive control: topical or oral diclofenac
versus no intervention, Outcome 6 Skin temperature reduction.
Review: Treatment for superficial infusion thrombophlebitis of the upper extremity
Comparison: 4 Topical or oral treatment versus inactive control: topical or oral diclofenac versus no intervention
Outcome: 6 Skin temperature reduction
Study or subgroup Diclofenac No treatment
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Topical diclofenac
Becherucci 2000 40 -0.33 (0.32) 40 0 (0.54) -0.33 [ -0.52, -0.14 ]
2 Oral diclofenac
Becherucci 2000 40 -0.27 (0.35) 40 0 (0.54) -0.27 [ -0.47, -0.07 ]
-2 -1 0 1 2
Favours Diclofenac Favours no treatment
Analysis 5.1. Comparison 5 Topical treatment versus active control: transdermal nitroglycerine versus
heparinoid gel, Outcome 1 Disappearance of signs and symptoms.
Review: Treatment for superficial infusion thrombophlebitis of the upper extremity
Comparison: 5 Topical treatment versus active control: transdermal nitroglycerine versus heparinoid gel
Outcome: 1 Disappearance of signs and symptoms
Study or subgroup
Transderm
nitroglycer-
ine Heparinoid Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Berrazueta 1993 22/22 18/18 1.00 [ 0.91, 1.10 ]
0.5 0.7 1 1.5 2
Favours nitroglycerine Favours heparinoid
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Analysis 5.2. Comparison 5 Topical treatment versus active control: transdermal nitroglycerine versus
heparinoid gel, Outcome 2 Time (h) to pain disappearance.
Review: Treatment for superficial infusion thrombophlebitis of the upper extremity
Comparison: 5 Topical treatment versus active control: transdermal nitroglycerine versus heparinoid gel
Outcome: 2 Time (h) to pain disappearance
Study or subgroup
Transderm
nitroglycer-
ine Heparinoid
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Almenar 1993 50 50.2 (39.7) 50 72 (39.9) -21.80 [ -37.40, -6.20 ]
-100 -50 0 50 100
Favours nitroglycerine Favours heparinoid
Analysis 5.3. Comparison 5 Topical treatment versus active control: transdermal nitroglycerine versus
heparinoid gel, Outcome 3 Time (h) to halving of erythema.
Review: Treatment for superficial infusion thrombophlebitis of the upper extremity
Comparison: 5 Topical treatment versus active control: transdermal nitroglycerine versus heparinoid gel
Outcome: 3 Time (h) to halving of erythema
Study or subgroup
Transderm
nitroglycer-
ine Heparinoid
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Almenar 1993 50 28.8 (24.2) 50 54.6 (34.5) -25.80 [ -37.48, -14.12 ]
-100 -50 0 50 100
Favours nitroglycerine Favours heparinoid
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Analysis 5.4. Comparison 5 Topical treatment versus active control: transdermal nitroglycerine versus
heparinoid gel, Outcome 4 Time (h) to halving of fibrous cord.
Review: Treatment for superficial infusion thrombophlebitis of the upper extremity
Comparison: 5 Topical treatment versus active control: transdermal nitroglycerine versus heparinoid gel
Outcome: 4 Time (h) to halving of fibrous cord
Study or subgroup
Transderm
nitroglycer-
ine Heparinoid
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Almenar 1993 50 58.3 (38.4) 50 84.5 (41.5) -26.20 [ -41.87, -10.53 ]
-100 -50 0 50 100
Favours nitroglycerine Favours heparinoid
Analysis 5.5. Comparison 5 Topical treatment versus active control: transdermal nitroglycerine versus
heparinoid gel, Outcome 5 Time (h) to halving of oedema.
Review: Treatment for superficial infusion thrombophlebitis of the upper extremity
Comparison: 5 Topical treatment versus active control: transdermal nitroglycerine versus heparinoid gel
Outcome: 5 Time (h) to halving of oedema
Study or subgroup
Transderm
nitroglycer-
ine Heparinoid
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Almenar 1993 50 31.2 (20.3) 50 33 (25.7) -1.80 [ -10.88, 7.28 ]
-100 -50 0 50 100
Favours nitroglycerine Favours heparinoid
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Analysis 5.6. Comparison 5 Topical treatment versus active control: transdermal nitroglycerine versus
heparinoid gel, Outcome 6 Adverse events.
Review: Treatment for superficial infusion thrombophlebitis of the upper extremity
Comparison: 5 Topical treatment versus active control: transdermal nitroglycerine versus heparinoid gel
Outcome: 6 Adverse events
Study or subgroup
Favours
nitroglyc-
erine Heparinoid Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Almenar 1993 2/50 0/50 49.4 % 5.00 [ 0.25, 101.58 ]
Berrazueta 1993 2/22 0/18 50.6 % 4.13 [ 0.21, 80.91 ]
Total (95% CI) 72 68 100.0 % 4.54 [ 0.55, 37.68 ]
Total events: 4 (Favours nitroglycerine), 0 (Heparinoid)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 1.40 (P = 0.16)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours nitroglycerine Favours heparinoid
Analysis 6.1. Comparison 6 Topical treatment versus active control: notoginseny cream versus heparinoid
cream, Outcome 1 Persistence of signs and symptoms at 48 h.
Review: Treatment for superficial infusion thrombophlebitis of the upper extremity
Comparison: 6 Topical treatment versus active control: notoginseny cream versus heparinoid cream
Outcome: 1 Persistence of signs and symptoms at 48 h
Study or subgroup Notoginseny Hirudoid Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Gouping 2003 0/34 5/31 0.08 [ 0.00, 1.44 ]
0.002 0.1 1 10 500
Favours Notoginseny Favours Hirudoid
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Analysis 6.2. Comparison 6 Topical treatment versus active control: notoginseny cream versus heparinoid
cream, Outcome 2 Mean time (h) for clinical resolution.
Review: Treatment for superficial infusion thrombophlebitis of the upper extremity
Comparison: 6 Topical treatment versus active control: notoginseny cream versus heparinoid cream
Outcome: 2 Mean time (h) for clinical resolution
Study or subgroup Notoginseny Hirudoid
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Gouping 2003 34 14.71 (7.55) 31 25.42 (13.21) -10.71 [ -16.01, -5.41 ]
-100 -50 0 50 100
Favours Notoginseny Favours Hirudoid
Analysis 7.1. Comparison 7 Topical treatment versus active control: topical versus oral diclofenac,
Outcome 1 Clinical response.
Review: Treatment for superficial infusion thrombophlebitis of the upper extremity
Comparison: 7 Topical treatment versus active control: topical versus oral diclofenac
Outcome: 1 Clinical response
Study or subgroup Topical Diclofenac Oral Diclofenac Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Becherucci 2000 24/40 24/40 1.00 [ 0.70, 1.43 ]
0.01 0.1 1 10 100
Favours topical Favours oral
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Analysis 7.2. Comparison 7 Topical treatment versus active control: topical versus oral diclofenac,
Outcome 2 Reduction in symptom severity.
Review: Treatment for superficial infusion thrombophlebitis of the upper extremity
Comparison: 7 Topical treatment versus active control: topical versus oral diclofenac
Outcome: 2 Reduction in symptom severity
Study or subgroup Topical Oral
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Becherucci 2000 40 -5.7 (3.13) 40 -4.82 (3.14) -0.88 [ -2.25, 0.49 ]
-10 -5 0 5 10
Favours topical Favours oral
Analysis 7.3. Comparison 7 Topical treatment versus active control: topical versus oral diclofenac,
Outcome 3 Pain reduction.
Review: Treatment for superficial infusion thrombophlebitis of the upper extremity
Comparison: 7 Topical treatment versus active control: topical versus oral diclofenac
Outcome: 3 Pain reduction
Study or subgroup Topical Oral
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Becherucci 2000 40 -2.25 (1.58) 40 -2 (1.6) -0.25 [ -0.95, 0.45 ]
-10 -5 0 5 10
Favours topical Favours oral
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Analysis 7.4. Comparison 7 Topical treatment versus active control: topical versus oral diclofenac,
Outcome 4 Oedema reduction.
Review: Treatment for superficial infusion thrombophlebitis of the upper extremity
Comparison: 7 Topical treatment versus active control: topical versus oral diclofenac
Outcome: 4 Oedema reduction
Study or subgroup Topical Oral
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Becherucci 2000 40 -2.05 (1.23) 40 -1.72 (1.48) -0.33 [ -0.93, 0.27 ]
-4 -2 0 2 4
Favours topical Favours oral
Analysis 7.5. Comparison 7 Topical treatment versus active control: topical versus oral diclofenac,
Outcome 5 Erythema reduction.
Review: Treatment for superficial infusion thrombophlebitis of the upper extremity
Comparison: 7 Topical treatment versus active control: topical versus oral diclofenac
Outcome: 5 Erythema reduction
Study or subgroup Topical Oral
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Becherucci 2000 40 -2.77 (1.84) 40 -2.2 (1.36) -0.57 [ -1.28, 0.14 ]
-4 -2 0 2 4
Favours topical Favours oral
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Analysis 7.6. Comparison 7 Topical treatment versus active control: topical versus oral diclofenac,
Outcome 6 Skin temperature reduction.
Review: Treatment for superficial infusion thrombophlebitis of the upper extremity
Comparison: 7 Topical treatment versus active control: topical versus oral diclofenac
Outcome: 6 Skin temperature reduction
Study or subgroup Topical Oral
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Becherucci 2000 40 -0.33 (0.32) 40 -0.27 (0.35) -0.06 [ -0.21, 0.09 ]
-1 -0.5 0 0.5 1
Favours topical Favours oral
A P P E N D I C E S
Appendix 1. CRS search strategy
#1 MESH DESCRIPTOR Thrombophlebitis EXPLODE ALL
TREES
1045
#2 MESH DESCRIPTOR Administration, Intravenous EX-
PLODE ALL TREES WITH QUALIFIERS AE
228
#3 MESH DESCRIPTOR Catheterization, Central Venous EX-
PLODE ALL TREES WITH QUALIFIERS AE
344
#4 phlebitis:TI,AB,KY 466
#5 thrombophlebitis:TI,AB,KY 1308
#6 thrombo-phlebitis:TI,AB,KY 3
#7 (vein near3 (pain* or tender* or induration or erythema)):TI,
AB,KY
42
#8 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 2294
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(Continued)
#9 MESH DESCRIPTOR Upper Extremity EXPLODE ALL
TREES
5286
#10 arm:TI,AB,KY 23977
#11 arms:TI,AB,KY 12796
#12 ((upper near2 extremit*)):TI,AB,KY 1565
#13 #9 OR #10 OR #11 OR #12 33831
#14 #8 AND #13 120
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We planned to use random-effects meta-analyses to summarise outcome data across studies. For outcomes where only a single study
was available, we used the fixed-effect option in RevMan (RevMan 2014).
Weplanned to explore between-trial heterogeneity by stratifying themain outcomes for trial characteristics, treatment and patient-related
features; however, these exploratory analyses turned out not to be feasible due to the limited number of RCTs and the heterogeneity of
study interventions and outcomes. For the same reasons, it was not possible to prepare a ’Summary of findings’ table nor the GRADE
assessment.
For the assessment of the risk of attrition bias we applied a conservative cut-off of 5% of participants randomised that we allowed to be
excluded from analyses. If the analyses was according to the intention-to-treat principle, but the number of participants with missing
data exceeded 20% per group or was differential between groups, we judged high risk of bias independent of the imputation methods.
N O T E S
We followed an in-house generated standard protocol, for the definition of outcomes, searches, risk of bias assessments, data-collection
and statistical analyses, The description of the methods therefore (partly) overlaps with our previous reviews in this field (Di Nisio
2012; Di Nisio 2014).
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